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Resumo 
 
A quimioterapia citotóxica encontra-se actualmente definida como sendo característica tradicional do 
tratamento oncológico; no entanto efeitos secundários adversos e a aquisição de ressistência a 
medicamentos quimioterapeuticos permanecem grandes desafios a ultrapassar. Nos últimos anos tem 
sido desenvolvido um grande esforço no sentido de encontrar novos compostos quimioterapeuticos 
com propriedades farmacodinâmicas e farmacocinéticas de forma a atingir maior especificidade 
tumoral e efeitos secundários reduzidos. Este trabalho teve como objectivo caracterizar o efeito anti-
tumoral de compostos de cloro-ouro e explorar os mecanismos pels quais estes exercem a sua 
actividade antiproliferativa, como parte deste esforço. Ensaios de citotoxicidade in vitro envolvendo os 
compostos cloro(trimetilfosfina)ouro(I) e cloro(trifenilfosfina)ouro(I) na linha A549 revelaram valores 
de IC50 de 44.4 e 30.0 μM respectivamente, e 3.3 e 5.4 μM na linha H1975 respectivamente. A 
citoselectividade dos mesmos compostos para linhas não tumorais, avaliada na cultura normal de 
fibroblastos revelou valores de IC50 de 7.7 e 19.1 μM respectivamente. Características morfológicas de 
apoptose foram igualmente confirmadas. Marcação por Hoechst 33258 nas linhas A549 e H1975 
quando expostas aos compostos ao seu valor de IC50 revelaram indícios de fragmentação nuclear e 
condensação da cromatina. Estes resultados foram ainda comprovados por citometria de fluxo. A 
dupla marcação com Anexina V-FITC e IP das células A549 após exposição ao composto B, 
demonstrou a capacidade de indução de mecanismos de morte celular por apoptose de uma forma 
dependente de dose. O composto cloro(trimetilfosfina)ouro(I) demonstrou ainda capacidade de induzir 
atrasos no ciclo celular sendo este efeito mais evidente na fase S. Interação dos compostos com a 
molécula de DNA revelou ser relativamente fraca ou inexistente  revelada através da incapacidade dos 
compostos de comprometerem a conformação de DNA plasmidíco. Os estudos proteómicos apesar de 
pouco conclusivos quanto ao mecanismo de acção dos compostos, permitiram identificar potenciais 
novos biomarcadores para o prógnostico de adenocarcinoma pulmonar. 
  
 Palavras Chave:  Cancro, Complexos de Cloro-ouro, Citotoxicidade, Apoptose, Ciclo Celular, 
Proteómica. 
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Abstract  
 
Cytotoxic chemotherapy at the present state is set as the traditional hallmark of oncological treatment; 
however host toxicity and drug resistance acquisition remain as main challenges to overcome. Over 
the past few years there has been a great effort towards finding new chemotherapeutic compounds 
with improved pharmacodynamic and pharmacokinetic properties in order to achieve higher cancer 
specificity and reduced undesirable side effects. The present work intended to characterize and 
elucidate the anti-tumoural effect of chlorogold complexes bearing phosphine or N,O-donor ligands, 
and explore the mechanisms by which they exert their antiproliferative properties as a part of this 
effort. Chloro(trimethylphosphine)gold(I) and Chloro(triphenylphosphine)gold(I) in vitro cell viability 
assays in A549 tumour cell line exhibited IC50 values of 44.4 and 30.0 μM respectively, plus 3.3 and, 
5.4 μM in H1975 respectively. Predisposition of the chlorogold complexes to target non-tumoural 
cells, evaluated in fibroblasts normal cell line, revealed an IC50 value of 7.7 and 19.1 μM respectively. 
Apoptosis morphological features were also confirmed. A549 and H1975 cell line exposure to both 
chlorogold complexes at their respective IC50 values, revealed nuclear fragmentation and chromatin 
condensation, observed by Hoechst 33258 staining. These results were further proven for by flow 
cytometry analysis. Double staining with Annexin V-FITC and Propidium Iodide in A549 after 
compound exposure revealed the ability to induce mechanisms of cell death by apoptosis in a dose-
dependent fashion. Chloro(triphenylphosphine)gold(I) was further proven to be able to induce cell 
cycle delay, this effect being especially evident for S-phase. Moreover compound interaction with the 
DNA molecule was proven to be either weak or inexistent through electrophoretic mobility assay 
revealed by the compounds’ inability to compromise plasmid DNA conformation. Proteomic studies 
even though not conclusive regarding chlorogold compounds’ mechanism of action, allowed the 
identification of new potential biomarkers for prediction of prognosis in non-small-cell lung 
carcinoma. 
 
 
Key-Words:  Cancer, Chlorogold complexes, Cytotoxicity, Apoptosis, Cell Cycle, Proteomics. 
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1. Introduction 
1.1. Cancer Etiology 
At any given moment an adult human is composed of approximately 10
15
 cells endowed with grand 
versatility and plasticity, paramount for different morphogenesis mechanisms and maintenance of 
adult tissues through cell turnover processes (Bertram, 2001). These numerous processes are usually 
tightly regulated by a network of overlapping molecular mechanisms which govern, among other 
factors, both cell proliferation and programmed cell death in a perfect balance. At the same time the 
genomic sequences’ susceptibility to corruption, either by intrinsic or extrinsic factors may tip this 
intricate homeostatic balance, leading to changes that are incompatible with an organismic structure. 
In other words cells that undergo this process, typically become unresponsive to normal cell signaling 
factors, and ―behave‖ in a organismic-independent fashion, often leading to altered cell proliferation 
programs and consequently to large populations of renegade cells that ultimately lead to cancer 
formation (Bertram, 2001; Weinberg, 2013). 
An important concept to grasp when considering cancer is that it is generally accepted as a genetic 
disease or as a group of genetic diseases, although not always heritable. Even though hereditary cancer 
predisposition syndromes have become more and more easily identified and studied, only 5 to 10 % of 
all cancer cases can actually be attributed to such genetic defects (Garber and Offit, 2005; Anand et 
al., 2008). In fact since the review by Doll and Peto in 1981 (Doll and Peto, 1981) it was concluded 
that the main causes of cancer are mainly related to environmental and lifestyle factors, accounting for 
the remaining 90 to 95 % of incidence cases (Anand et al., 2008).  
 1.1.1. From Carcinogens and Lifestyle Habits to Genetic Influence 
Among other causes mutations can arise from exposure to a series of environmental mutagens, such as 
cigarette smoke, alcohol, radiation, infectious agents, diet related and many others described 
extensively elsewhere (Baan et al., 2009; Bouvard et al., 2009; El Ghissassi et al., 2009; Grosse et al., 
2009; Jemal et al., 2010; Secretan et al., 2009; Straif et al., 2009). The link between environmental 
mutagens and the incidence and mortality cancer rates across the world are particular evident by 
observing trends and habits over the last century (Anand et al., 2008; World Cancer Report, 2008). In 
fact while the incidence and mortality rates are actually decreasing for the majority of western 
countries, these are on the rise for several less developed and economically transitioning countries due 
to the adoption unhealthy lifestyles, typical of western countries, such as smoking, physical inactivity, 
and the consumption of high calorie foods (Jemal et al., 2010). Lifestyle-cancer associations have 
been extensively studied. For instance increases in intakes of fat, red meat or processed meat and 
alcohol, alongside with obesity and lack of physical exercise, have shown through a series of cohort 
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and meta-analysis studies, to increase to variable extent, the risk of contracting colorectal, breast and/ 
or prostate cancer (World Cancer Report, 2008). Furthermore the relationship between diet and cancer 
becomes more obvious when observing incidence rates among populations in migratory studies 
(McCracken et al., 2007). For instance Asians have been shown to have 25 times lower incidence of 
prostate cancer and 10 times lower incidence of breast cancer (Anand et al., 2008) however the rates 
of these types of cancer tend to increase in migrating Asian-American populations indicating that they 
have been subjected to a more Western lifestyle, becoming simultaneously more prone to the same 
risk factors associated for these specific cancers (McCracken et al., 2007). Smoking and related 
mutagens on the other hand, can almost be considered as particular class due to its importance and 
influence on the tinkering of specific molecular networks and mechanisms and consequently on the 
emergence of cancer. In particular cigarette smoke is known to contain approximately 60 mutagens 
(Takahashi et al., 2011) ranging from polycyclic aromatic hydrocarbons to specific nitrosamines. 
Exposure to such mutagens to airway epithelial cells through continuous smoking leads to severe 
molecular lesions and diminished repair capability, being accountable as the major cause of cancer in 
humans, and correlated to 13 different types such as lung, oral cavity, nasal cavity and nasal sinuses, 
pharynx, larynx, oesophagus, stomach, pancreas, liver, urinary bladder, kidney, uterine cervix and 
myeloid leukaemia (World Cancer Report, 2008). Benzopyrenediol epoxide is one example of a 
cigarette smoke metabolite that as actually been etiologically linked to lung cancer, which is known to 
form adducts on guanine residues with a particular incidence on the tumour suppressor gene TP53 
(Lemjabbar et al., 2003). Similarly DNA adduction and mutagenesis were also reported for aromatic 
amines derived from cigarette smoking (Besaratinia and Tommasi, 2013). Recent studies have also 
connected the capacity of tobacco smoke to trigger chronic inflammation, through IKKβ and JNK1 
pathway activation (Takahashi et al., 2011), which has been extensively demonstrated to play decisive 
roles at different stages of tumour development (Grivennikov et al., 2010). 
Even though these lifestyle habits and associated mutagens further emphasize the effect and burden 
that the surrounding environment has over the organismic structure of the human body and its genetic 
constitution it is known that these factors alone do not entirely justify the onset and emergence of 
cancer. For example it is clear that intrinsic factors resulting from by-products of endogenous 
processes trigger important molecular alterations at the genetic and epigenetic level, fundamental for 
promoting the emergence of cancer. Reactive oxygen species (ROS) for instance, such as superoxide 
radical, hydrogen peroxide, singlet oxygen or hydroxyl radical have reportedly demonstrated to have a 
significant role in genomic instability (Kanvah et al., 2010). Particularly genomic instability caused by 
ROS seems to involve mainly guanine modifications causing G→T transversions (Kanvah et al., 
2010). Mutations range from oxidized purines and pyrimidines to single strand breaks and instability 
formed directly or by DNA repair processes (Waris and Ahsan, 2006). 
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On the other hand DNA replication itself can be considered as a source of mutational events. DNA 
replication enzymes inherent mutation rate is as little as 1 in 10
9
 (Loeb et al., 1974) however error 
prone phenotypes in DNA replication enzymes or in translesion DNA inherently increase this error 
rate, leading to genomic instability and to cancer susceptibility (Suzuki and Takahashi, 2013). Genetic 
disturbances can range from chromosome alterations to point mutations which ultimately can disable 
tumour suppressor genes or activate proto-oncogenes that respectively can alter cell proliferation and 
survival pathways (Suzuki and Takahashi, 2013). 
1.2. Incidence and Mortality Rates 
Cancer burden worldwide is known to be increasing over the years, in part as a reflection of 
westernized habits, but also as consequence of the continuous growth and aging of the world’s 
population (Jemal et al., 2011). Accordingly to the most recent data from the World Health 
Organization (WHO), in 2012 alone it was estimated 14.1 million new cancer cases, alongside with 
8.2 million related deaths, turning cancer into a major leading cause of death worldwide (―World 
cancer factsheet,‖ 2014). Of particular importance 44 % of all cancer cases and 53 % of related deaths 
occurred in low or medium developing countries (Rise, 2013). Globally, the most commonly 
diagnosed cancers were those of the lung (1.8 million, 13.0 % of the total), breast (1.7 million, 11.9 
%), and colorectal (1.4 million, 9.7 %) whereas the most common causes of cancer death were cancers 
of the lung (1.6 million, 19.4 % of the total), liver (0.8 million, 9.1 %), and stomach (0.7 million, 8.8 
%) (Figure 1.1) (―GLOBOCAN,‖ 2012). 
Figure 1.1 – Incidence and mortality rates worldwide for most common cancers (Adapted from ―GLOBOCAN,‖ 2012). 
The close relationship evidenced between incidence and mortality rates for some types of cancer such 
as lung, colorectal and stomach, allows not only to infer about social and cultural habits, as well as 
draws attention to a more pressing issue that is the inefficiency of current therapeutic strategies 
applied for these same cancers. In the end with current trends it is predicted that globally, cancer 
burden will increase significantly, up to 19.3 million new cancer cases per year by 2025 
(―GLOBOCAN,‖ 2012; ―World cancer factsheet,‖ 2014) stressing out ever more the importance of a 
complete understanding over the underlying molecular mechanisms that lead to the onset of cancer, 
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and of the establishment of priorities and control strategies to fray down the overwhelming spread of 
cancer globally. 
 1.2.1. Lung Cancer Incidence 
In 2012 1.8 million new cases of lung cancer were estimated (―GLOBOCAN,‖ 2012), compared with 
1.6 million in 2008 and is considered the most common cause of death in developing and developed 
countries (Jemal et al., 2011). Notably in Europe and in Eastern Asia the incidence rates for men 
surpasses the 50 cases per 100000 persons while in women these rates are slightly lower due to 
historic variants. The highest estimate rates for women are evidenced for North America and Northern 
Europe with values of 32.8 and 23.7 cases per 100000 persons respectively. In contrast low developing 
countries in the Western and Middle Africa area report the lowest incidence rates in an order of 
magnitude of 0.8 to 1.1 cases per 100000 persons (―GLOBOCAN,‖ 2012). 
 
Figure 1.2 – Lung and bronchus cancer incidence and mortality rates in the United States (―Cancer of the Lung and 
Bronchus - SEER Stat Fact Sheets,‖ 2010). 
Despite these statistical numbers the fact is that the incidence and mortality rates for lung cancer is 
actually decreasing for the majority of western countries including many European countries (Jemal et 
al., 2010). This trend is particularly evident when observing the decrease of lung and bronchus cancer 
incidence and mortality rates in the United States (US) over the years (Figure 1.2), in particular since 
it peaked in middle of the last century. Tobacco control interventions, increased cigarette prices, 
restriction of tobacco advertising and an awareness rising against the dangers of smoking, among other 
antismoking strategies are between some of the control measures taken by developed countries that 
actually justify this specific decline in incidence and mortality rates. To put in perspective recent 
studies demonstrate that tobacco control implementations in the US, during the period 1975–2000, 
have averted 32 % of lung cancer deaths due to changes in smoking behaviours (Moolgavkar et al., 
2012). Nevertheless the high overall ratio of mortality to incidence (around 0.87) forces a pattern 
where mortality rates closely follows those of incidence (―Cancer of the Lung and Bronchus - SEER 
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Stat Fact Sheets,‖ 2010), emphasizing the continuous need for better control programs and particularly 
treatment strategies. 
1.3. Cancer Biology: Cellular and Molecular Basis 
 1.3.1. Genomic instability and other Contributing Factors for Neoplasic 
Transformation 
The occurrence of aberrational events within the genome, either of temporary or permanent nature, 
commonly referred to as genomic instability in the literature, are often associated and characteristic of 
most cancers (Negrini et al., 2010). Both numerical aberrations and structural rearrangements of 
chromosomes or even the accelerated rate of chromosomal alterations, which result in gains or losses 
of whole chromosomes as well as inversions, deletions, duplications and translocations of large 
chromosomal segments, are the most frequent form of genomic instability. Although expansion and 
contraction of the number of oligonucleotides repeats in microsatellite sequences have also been 
described (Negrini et al., 2010; Gordon et al., 2012).  
Even though the genomic instability in hereditary cancers is well understood, and strongly linked to 
mutations in DNA repair genes such as those involved in the nucleotide and base excision repair 
processes (BRAC1, BRAC2, MSH2, MYH), the molecular basis is not so clear for sporadic cancers. 
Recent reports have however shed some light over this subject mentioning that mutations in caretaker 
genes (like DNA repair genes) are infrequent in early cancer development (69 to 97 % of cancers did 
not present mutations in caretaker genes) and propose oncogene-induced DNA replication stress as the 
most likely responsible for the processes involved in genomic instability for these cancers (Negrini et 
al., 2010). With increased genomic instability, spontaneous DNA damage events are more likely to 
occur as a result of DNA replication stress (compromised fidelity of replication enzymes). Events such 
as depurination due to N-glycosidic breakage, or deamination of cytidine to uridine, and deamination 
of methylcytosine to thymidine greatly increase the mutagenic susceptibility (Bertram, 2001), 
selectively promoting specific mutations as those occurring in TP53, resulting in cells evading death 
and senescence (Figure 1.3) (Negrini et al., 2010; Farnebo et al., 2010).  
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Figure 1.3 – p53 as a barrier against tumour development. Oncogene activation or deregulated cell cycle progression leads to 
stalled DNA replication forks and activation of the DNA damage response (DDR) (Adapted from Farnebo, et al., 2010) 
In addition a recent cohort study involving 3281 tumours across 12 tumour types as part of the Cancer 
Genome Atlas effort, has demonstrated that TP53 is in fact the most frequently mutated gene (Kandoth 
et al., 2013). Other reports have actually linked TP53 mutations to over 50 % of all human cancers 
including lung carcinoma where it represents an extremely common event (Vincenzi et al., 2006; 
Farnebo et al., 2010; Wong, 2011). Furthermore PIK3CA was found to be second most frequently 
mutated gene representing a frequency of over 10 % of most cancer types (Kandoth et al., 2013), and 
the remaining frequently deregulated genes mainly encoded classical oncoproteins like epidermal 
growth factor receptor (EGFR), KRAS and NRAS family, phosphatase and tensin homologue (PTEN) 
(Negrini et al., 2010; Kandoth et al., 2013). 
Apart from the genetic mechanisms described above, epigenetic studies are gaining increasing 
relevance as more and more evidences point out a more significant role for DNA alterations and 
associated chromatin changes in gene expression and in tumourigenesis (Waldmann and Schneider, 
2013).  Hallmarks of epigenetic changes like DNA methylation and post-translational modifications of 
histones may contribute to oncogenesis through transcriptional silencing of tumour suppressor genes 
(Waldmann and Schneider, 2013). Global hypomethylation, possibly the first epigenetic modification 
to actually be linked with tumourigenesis is commonly observed in malignant cells being associated 
with chromosomal instability in colorectal cancer (Berman et al., 2012). However methylation 
changes occurring at CpG islands equally play an important role in modelling transcriptional 
responses. Hypermethylation frequency of such regions was found to be often high. In fact typically 
unmethylated CpG islands in promoter genes, around 5 to 10 %, have actually been confirmed to be 
methylated in various cancer genomes (Dawson and Kouzarides, 2012; Waldmann and Schneider, 
2013; Esteller et al., 2001), but the relevance of this alterations is still to be deciphered. 
Regarding the interplay between histone modifications and cancer, a few mutations have been found 
through genome sequencing of tumours. Specific point mutations in histones H1.5, H3.1, H3.3 have 
been reported and are known to change chromatin conformation, and in particular H3 mutations seem 
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to be linked to some specific cancers such as gliomas. Nevertheless all in all, the consequences of such 
mutations remain to be unravelled and further studied (Waldmann and Schneider, 2013). 
Additionally specific mutations in numerous epigenetic gene regulators have also been found in 
several cancers which in part might explain differences in methylation patterns during oncogenesis. 
For example histone-lysineN-methyltransferase gene, MLL2, has been recurrently found mutated in 
several cancers (Kandoth et al., 2013), but in particular high incidence in follicular lymphoma. Plus 
UTX, a histone demethylase has been found to be mutated in up to 12 histological distinct cancers 
(Dawson and Kouzarides, 2012). Mutations were still found in other chromatin remodelling genes 
such as MLL3, MLL4 for bladder, lung and endometrial cancers, and demethylase gene KDM5C in 
kidney carcinoma (Kandoth et al., 2013). By understanding the mechanisms involved in epigenetic 
control and their associated mutations, the foundations are laid for the production of new drugs and 
treatments to override such alterations that may cause cancer and many other diseases. 
Other factors such as proteotoxic, metabolic and oxidative stress have reportedly influence the process 
of neoplasic transformation and tumourigenesis. In regards to metabolic stress, for instance, it is 
known that tumoural cells produce ATP through glycolysis which in turn grants tumoural cells an 
adaption to hypoxia conditions, and allows for the acidification of the surrounding environment. In 
turn it facilitates tumour invasion and immune suppression. More detailed information is presented 
elsewhere (Luo et al., 2010). 
 1.3.1.1 p53 Tumour Suppressor 
Despite the fact that each cancer is characterized by a specific set of mutations, as already mentioned 
above, the high frequency of TP53 mutations in a broad spectrum of cancers, draws much attention to 
it and its particular biological functions (Olivier et al., 2010), hence it will be further analyzed here. 
The p53 tumour suppressor has been established as a nucleophosprotein that plays an important role in 
cellular homeostasis (Steele and Lane, 2005; Alarcon-Vargas and Ronai, 2002). Its importance comes 
not only from the fact that is often mutated in over 50 % of all cancers, but also due to the increasing 
number of biological processes that it has been implicated in, such as cell cycle arrest, senescence, 
apoptosis, autophagy, angiogenesis, metabolism, and aging (Sullivan et al., 2012; Farnebo et al., 2010; 
Vousden and Prives, 2009). There are also increasing evidences that, even though p53 is best 
described as transcription factor, some of the biological processes in which it has been involved are 
cytosolic and transcription independent (Figure 1.4) (Green and Kroemer, 2009; Vousden and Prives, 
2009). Particularly p53 biological activity is triggered when accumulated in response to several 
cellular stress inputs, including DNA damage by exogenous carcinogens, oncogene activation, 
telomere erosion, hypoxia, loss of cell adhesion, compromised microtubule scaffolding, transcription 
blockage and others (Farnebo et al., 2010; Green and Kroemer, 2009). 
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Figure 1.4 – p53 intricate circuit board of biological processes and their respective regulation, with discriminated 
transcriptional and cytoplasmic roles (Adapted from Vousden and Prives, 2009). 
In turn it is the ―impairment‖ of the auto-regulatory loop between Mdm2 and p53 (which regulates the 
overall stability and activity of p53 through post-translational modifications) through these cellular 
stress inputs that lead to the accumulation of p53 (Alarcon-Vargas and Ronai, 2002). This then 
triggers the activation of p53 target genes, such as p21, GADD45, Bax, Puma, Noxa, DR5, p53AIP, 
PIDD, and others, triggering apoptosis, autophagy, cell cycle arrest or senescence (Farnebo et al., 
2010; Alarcon-Vargas and Ronai, 2002). It is then easy to understand that activation of such pathways 
by p53, in normal conditions, leads to tumour suppression (Figure 1.4). 
For instance cell cycle arrest can be achieved through p53 mediated activation of the cyclin-dependent 
kinase inhibitor p21, alongside with target genes such as 14-3-3 sigma and GADD45 (Vousden and 
Prives, 2009). Particularly p21 inhibits cell cycle progression mainly through the inhibition of CDK2 
and CDK1, which are involved in a myriad of phosphorylation cascades (such as the phosphorylation 
of RB; key for cell cycle entry), leading to a temporary growth arrest in G1/S stage of the cell cycle. 
Plus p21 binding to proliferating cell nuclear antigen hinders DNA polymerase activity, inhibiting 
replication and allowing for the activation of DDR processes (Manuscript, 2010). Together these 
processes concede time for DNA repair. 
In turn apoptosis induction by p53 is not so clearly understood, however extensive literature report two 
major mechanisms; transcription dependent and transcription independent or cytoplasmatic (Bertram, 
2001; Green and Kroemer, 2009). Generally in the nucleus p53 is responsible for dictating the 
expression levels of numerous pro-apoptotic molecules, such as BAX, PUMA, NOXA, BID that will 
ultimately lead to mitochondrial outer membrane permeabilisation (MOMP). In the cytoplasm the fate 
of the cell greatly depends on the extrinsic stress factor, and in the counterbalance between pro-
apoptotic versus anti-apoptotic proteins. Hence the interactions between p53 and proteins of the Bcl-2 
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Figure 1.5 – Schematics illustrating the 
multistage facet of carcinogenesis. Premalignant 
cells are the result of an initiating event such as a 
compromised tissue repair response, conferring an 
enhanced survival. Sequentially early tumour 
nodules would be the result of the accumulation 
of successive mutational events, like immune 
evasion or epigenetic modifications. In the end 
angiogenesis factors and loss of cell adherence 
would lead to metastasis and to the formation of 
an advanced tumour  (Adapted from (Grivennikov 
et al., 2010). 
 
or Bcl-xL family can either lead the promotion or inactivation of pro-apoptotic Bcl-2 multi-domain 
proteins and consequently to cell death or cell survival (Chipuk and Green, 2006). 
In short p53 specific DNA binding and transcriptional 
regulation of target genes can be hindered by a myriad 
of mutations which in turn compromise the ability of a 
controlled response to tumour suppression, and the wide 
number of other biological processes in which it is 
involved. Plus contrary to general believe, recent 
reports state that some of the p53 mutations, besides 
abrogating tumour suppression and general 
transcriptional regulation circuit board, actually endow 
the protein a set of characteristics that have been found 
to be fundamental for oncogenesis (Oren and Rotter, 
2010). 
1.3.2. Mechanisms of Carcinogenesis: A 
Multi-step Process 
As it can be seen cancer is not the result of a single gene 
defect, but rather a complex multigenic disease. In other 
words cancer is the end result of a series of alterations 
that have taken part over a long period of time, 
nonetheless the vast number of epi- and genetic 
alterations found across different cancers, not all 
contribute and have an active role to the onset of cancer. 
Carcinogenesis is rather likely to be driven only by a 
select few mutations (gain of an oncogene or the loss of 
a tumour suppressor), and the remaining alterations may 
or may not potentiate the overall process, often being 
called ―passenger‖ mutations as opposed to driver 
mutations (Ashkenazi et al., 2008; Tomasetti et al., 
2013; Luo et al., 2010). As already mentioned above 
these mutations compromise homeostatic cellular 
processes and tend to tip the delicate balance between 
cell proliferation and cell death, often leading to an 
abnormal and uncontrolled cell growth, giving rise to what it is clinically referred to as neoplasic 
growth (Bertram, 2001).  
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Typically the process by which mutations occur is complex and sequential. At least 4 to 7 independent 
events must take place in order for a cell to be considered as tumourigenic (Ashkenazi et al., 2008; 
Bertram, 2001). The complexity that carcinogenesis represents, led to the creation of models that try to 
explain the progression of mutations that are known to take part during this process (Ashkenazi et al., 
2008; Tomasetti et al., 2013). The most renowned, probably for its simplicity, models carcinogenesis 
as multistep process of mutation acquisition, considering a homogenous cell population, in what is 
known as the ―initiation, promotion and progression‖ model (Figure1.5) (Ashkenazi et al., 2008; 
Jakóbisiak et al., 2003). In this model a tumour is initiated by a driver mutation in a gene typically 
involved in the control of cell proliferation, evasion of apoptosis and/or genomic integrity (oncogenic 
pathways), endowing the cell with superior proliferation characteristics, or any other survival 
advantage over the remaining cell population. With each successive clonal expansion of such cells, 
these become susceptible to additional mutational events that are accumulated over time and further 
contribute for an enhanced survival. Eventually a third event would promote an irreversible process by 
which the malignant potential of the cells would be enhanced, leading to tissue invasion and 
metastasis. Events such as increased genomic instability (which is a characteristic of all developed 
cancers), cytokine and chemokine modulation of tumour cells as result of inflammation, angiogenesis 
induction, and protease production to promote loss of cell adherence and cell detachment, all 
contribute for the development of a malignant tumour (Jakóbisiak et al., 2003; Tomasetti et al., 2013; 
Grivennikov et al., 2010). 
Overall, independently of the manifold mutational combinations acquired during the multistep 
development of carcinogenesis, these will ultimately result in a common set of characteristics or 
hallmarks that dictates and characterizes the malignant phenotype (Pietras and Ostman, 2010; 
Hanahan and Weinberg, 2011). These include sustained proliferative signalling, insensitivity to anti-
growth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis (Figure 1.6)(Pietras and Ostman, 2010; Hanahan and Weinberg, 2011). 
Pivotal for a sustained proliferative growth, cancer cells must be able to be self-sufficient in growth 
signals in order to outgrow normal tissue cells, and to establish the three dimensional scaffolding 
necessary for tumour microenvironment interactions, and ultimately tumour promotion and 
progression.  
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Figure 1.6 – Illustration of the six hallmarks that characterize and influence the process of carcinogenesis (Adapted from 
Hanahan and Weinberg, 2011). 
A variety of possible mechanisms allow for such event to occur, ranging from an overexpression of 
receptor proteins, to autocrine proliferative stimulation and even constitutive activation of downstream 
components involved in cell proliferation pathways (H-RAS oncogene) (Hanahan and Weinberg, 
2011). Secondly the evasion of growth suppressors, very much resembles as ―taking away the brakes‖ 
that are meant to prevent continuous proliferation. In other words cancer cells are able to abrogate 
many of these powerful control programs that are often many times related with the biological 
function of tumour suppressor genes such as those already mentioned here, like TP53 or the 
retinoblastoma gene (RB) involved in the control of cell cycle progression (Hanahan and Weinberg, 
2011). Additionally during tumour progression to the malignant state, tumoural cells must ―employ‖ a 
variety of strategies to circumvent the complex apoptotic machinery programs that act as barriers to 
cancer in normal tissues. TP53 loss of function is the most frequent cause that leads to a compromised 
activation of the apoptotic machinery programs, however other alterations can also allow tumour cells 
to bypass apoptosis-triggering mechanisms, such as constitutive expression of anti-apoptotic factors 
(Bcl-2, Bcl-xL) or the promotion of survival regulators and pathways, to name a few (Hanahan and 
Weinberg, 2011). Due to the ―faulty‖ nature of DNA replication itself, tumoural cells must also 
acquire a limitless replicative potential otherwise the sustained proliferative growth would eventually 
progressively shorten the telomeres (tandem hexanucleotide repeats at the end of chromosomes) 
leading to the inability to protect the ends of chromosomal DNA, threatening cell viability. In fact 
telomerase activity is virtually absent in normal cells, while it is expressed in significant levels in the 
vast majority of cancers, hence circumventing telomere shortening and chromosome instability while 
simultaneously acquiring replicative immortality (Hanahan and Weinberg, 2011). Additionally 
tumours are known to be able to induce new blood vessel growth as form to obtain an unlimited 
supply of nutrients and oxygen as well as a form to create their own waste management pipeline to 
remove sub metabolic products such as carbon dioxide. Angiogenesis is known to be orchestrated by 
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several regulators, positive and negative ones, such as vascular endothelial growth factor (VEGF) or 
platelet-derived growth factor (PDGF) to name a few. For instance VEGF expression can be 
upregulated by stimulating factors such as hypoxia or oncogene activation (Hanahan and Weinberg, 
2011; Bergers and Benjamin, 2003). Also worth mentioning is that the rapid genesis of new blood 
vessels associated with chronic exposure to angiogenic activators leads to an abnormal overall 
vasculature different from their normal counterparts sharing different characteristics of several types 
of blood vessels (Bergers and Benjamin, 2003). Finally all cancers will ultimately engage in tissue 
invasion and the formation of metastasis. Namely loss of cell adhesion between the cells of the tumour 
mass allows their disaggregation contributing to an enhanced malignant phenotype, characterized by 
massive tissue invasion and multiple metastasis formation. Abrogation of cadherin/catenin expression 
levels, in particular E-cadherin has been highly associated with malignant phenotypes and micro-
metastases. Additionally these cells also typically present enhanced cell motility, further assisting the 
invasion phenotype, through the expression of adhesion molecules like N-chaderin associated with cell 
migration processes. Also tumour cells are known to produce a vast range of proteases, such as 
cathepsins that allow the detachment from broad range of extracellular matrix/basement membrane 
components, including proteoglycans and collagens (Brooks et al., 2010; Hanahan and Weinberg, 
2011). 
Other emerging hallmarks include the deregulation of cellular energetics, as already mentioned above 
were cancer cells redirect their energy production to glycolysis, and the evasion from the hosts’ 
cellular and molecular immune mechanisms that are set to destroy cancerous cells such as natural 
killer cells (Hanahan and Weinberg, 2011).  
 1.3.3. Mechanisms of Cell Death: Apoptosis, Autophagy & Necrosis 
Ever since the pioneering work in Caenorhabditis elegans revealed the genetic programme of 
apoptosis, cell death in the broader sense of this term, has been seen as a fundamental process often 
governed by an intricate array of regulators and signalling pathways, with an active role in overall 
development and in the maintenance of cellular homeostasis (Elmore, 2007; Vanden Berghe et al., 
2014). Until recently apoptosis and necrosis were considered to be the only forms of cell death, with 
apoptosis being seen as the fundamentally orchestrated cellular process in physiological and 
pathological conditions (Wong, 2011), and necrosis as the result of physicochemical abuse leading to 
an uncontrolled swelling, organelle dysfunction and cell lysis (Vanden Berghe et al., 2014; Ouyang et 
al., 2012). Both of these cell death modes have already been extensively described and are relatively 
well understood (Elmore, 2007; Patel et al., 2010; Taylor et al., 2008; Vanden Berghe et al., 2014). 
Recent understandings however have led to conceptual advances regarding other forms of cell death. 
Autophagy is a particular example which has been shown to be important in several regulatory 
pathways under certain physiological conditions. It is considered as catabolic process involving the 
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formation of double-membrane vesicles called autophagosomes, responsible for the turnover of large 
portions of cytoplasm including several organelles and other specific macromolecules (Mariño et al., 
2014; Ouyang et al., 2012). Plus it is considered as general protective response system that it is 
triggered under certain environmental stress such nutrient shortages (Mariño et al., 2014). Over the 
years attempts in discovering the underlying mechanisms related to these forms of cell death have 
simultaneously led to the uncovering of many other, such as necroptosis, parthanatos, oxytosis, 
ferroptosis, ETosis, NETosis, pyronecrosis or pyroptosis (Galluzzi et al., 2012; Vanden Berghe et al., 
2014). Were some opinions diverge, others attempt to unify perspectives over cell death and recently 
some authors have proposed that these several forms of cell death are merely different forms of 
regulated necrosis (Vanden Berghe et al., 2014). Even though necrosis has been generally considered 
an uncontrolled process resultant from physical damage of some sort, the discovery of key regulators 
of necrotic death, such as receptor interacting protein kinases (RIPK1 and/or RIPK3) led to the 
establishment of necrosis as a possible genetically controlled cell death mode (Ouyang et al., 2012; 
Vanden Berghe et al., 2014). This regulated necrosis is known to be independent of caspase activation, 
and to lead to a set of biological processes such as, mitochondrial dysfunction, increased cell volume 
(oncosis), production of ROS, and ultimately lysis. The immunogenic nature of necrosis resultant from 
the extravasation of their inner components (pro-inflammatory molecules) to the extracellular 
environment further lead to inflammatory responses that contribute for tumourigenesis (Grivennikov 
et al., 2010). 
Understanding the underlying mechanisms of these modes of cell death is crucial as it will lay the 
groundwork and study platforms for different chemotherapy strategies, while simultaneously allowing 
for a better knowledge of the consequences of such strategies.  
 1.3.3.1. Apoptosis 
The process of programmed cell death by apoptosis is best described as series of molecular and 
architectural cellular alterations controlled by an intricate system of energy-dependent biochemical 
mechanisms and regulators (Taylor et al., 2008; Elmore, 2007). The positive induction of such 
mechanisms leads to distinct morphological alterations, such as cell shrinkage and convolution, 
detachment from the extracellular matrix, chromatin condensation, mitochondrial; Golgi; endoplasmic 
reticulum (ER) fragmentation, nuclear fragmentation and blebbing of the plasma membrane while 
maintaining its integrity (Elmore, 2007; Orrenius et al., 2011). Each bleb eventually culminates into an 
individual vesicle, termed apoptotic body, which contain the remaining cytoplasmic components 
resultant from the controlled ―demolition‖ of the overall cellular architecture. In the end these 
apoptotic bodies are rapidly consumed by specific cellular counterparts like macrophages that 
recognize particular molecular surface markers, thus avoiding an unwanted immunogenic response, 
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since there isn’t an extravasation of the intracellular content to the surrounding tissues (Taylor et al., 
2008; Orrenius et al., 2011).       
The entire process that comprises apoptosis is vast and complex; hence the major biochemical 
pathways and regulators will only be discussed here briefly. The extensive research upon apoptosis 
has led to the identification of three major apoptotic pathways: the extrinsic or death receptor pathway, 
the intrinsic or mitochondrial pathway and the perforin-granzyme-dependent pathway (Figure 1.7) 
(Elmore, 2007; Taylor et al., 2008). The perforin-granzyme-dependent pathway that will be addressed 
in less detail is best described as to involve the cytotoxicity of T-cells which induce apoptosis either 
by granzyme B or granzyme A. 
Figure 1.7 – Illustration of the different activation pathways of apoptosis. Extrinsic pathway (1) as well as intrinsic (2) and 
granzime B pathway (3) are depicted alongside with their main intervenients. Irrespective of the actual route to caspase 
activation, all pathways lead to the activation of the major effector caspases, caspase-3, caspase-6 and caspase-7, and these 
carry out much of the proteolysis that is seen during apoptosis (Adapted from Taylor et al., 2008).  
 
Independently of the activation pathway triggered all of these seem to converge into the same 
biochemical pattern, which is the activation of caspases (Orrenius et al., 2011; Elmore, 2007). 
Caspases are present in all cells in a form of precursor enzymes or zymogens, and once activated are 
responsible for most if not all the biochemical changes that occur as apoptosis progresses towards its 
end (Taylor et al., 2008). Their proteolytic activity cleaves proteins at their aspartic residues leading to 
protein cross-linking, DNA fragmentation (down to 200 bp fragments) and eventually to the 
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morphological alterations already mentioned above (Elmore, 2007). A noteworthy concept to keep in 
mind is that once activated, cells seemingly become committed to a programmed cell death. At the risk 
of being over simplistic the extrinsic pathway, as the name suggests, is activated by the binding of 
extracellular death ligands, such as FasL (fatty acid synthetase ligand) or tumour necrosis factor-α 
(TNFα), to their respective transmembrane death receptors (Wong, 2011). The family of 
transmembrane death receptors is vast including more than 20 proteins with a broad range of 
biological functions (Ouyang et al., 2012; Schulze-bergkamen and Krammer, 2004), however the best 
described and more extensively studied are type 1 TNF receptor (TNFR1) and a related protein Fas 
(CD95- FasL receptor) (Schulze-bergkamen and Krammer, 2004; Wong, 2011). Upon ligation to their 
cognate ligands, receptor trimerization occurs as well as clustering of death domains and the 
recruitment of adaptor proteins such as Fas-associated death domain (FADD) or TNFR1-associated 
death domain (TRADD) which in turn form a protein complex known as the death-inducing signalling 
complex (DISC) (Fulda and Debatin, 2006; Wong, 2011). Once formed this protein complex is 
responsible for the oligomerisation of pro-caspase-8 leading to its activation through self-cleavage. In 
turn caspase-8 can proteolytically activate downstream caspase effectors such as caspase-3 and 
caspase-7, or in other situations it can promote the activation of BH3-only protein BID (BH3- 
interacting domain death agonist) through crosstalk with the intrinsic pathway. After proteolytic 
activation by caspase-8, the truncated BID induces mitochondrial outer membrane permeabilisation 
(MOMP) by the formation of transmembrane BAX-BAK channels (BAX-Bcl-2-associated X protein), 
consequently causing the release of cytochrome c and assembly of the apoptosome (Figure 1.7). The 
last one is multi-protein complex, comprised by 7 molecules of apoptotic protease-activating factor-1 
(Apaf-1), caspase-9 and cytochrome c that binds to the C-terminal region of Apaf-1. Together this 
complex is responsible for further amplifying the apoptotic signal in the intrinsic pathway (Taylor et 
al., 2008; Fulda and Debatin, 2006). 
The intrinsic pathway on the other hand is marked by the diverse stimuli that trigger it. Internal stimuli 
like hypoxia, irreparable DNA damage, high concentrations of Ca
2+
, oxidative stress by ROS, 
temperature and osmolality changes, nutrient shortages and others, may induce changes in the inner 
mitochondrial membrane that result in the loss of transmembrane potential leading to the release of 
pro-apoptotic molecules into the cytosol (Wong, 2011; Portt et al., 2011). More specifically these 
stimuli lead to p53 mediated activation of members of the BH3-only protein family (e.g., PUMA, 
NOXA, BID), which when above a crucial threshold in the cytosol surpasses the inhibitory effect of 
the anti-apoptotic B-cell lymphoma-2 (BCL-2) family members (Taylor et al., 2008). It is in fact the 
balance between the pro- (e.g. Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim and Hrk) and anti-apoptotic (e.g. 
Bcl-2, Bcl-XL,Bcl-W,Bfl-1 and Mcl-1) proteins within the cytosol that defines whether apoptosis is 
carried out or not (Wong, 2011). BH3-only proteins promote the assembly of BAX-BAK channels in 
the mitochondria causing MOMP the consequent release of intermembrane proteins such as 
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cytochrome c, second mitochondria-derived activator of caspase/directed IAP (inhibitory of apoptosis 
proteins) binding protein with low pI (Smac/ DIABLO), and apoptosis-inducing factor (AIF). Among 
these cytochrome c plays perhaps the most important part, as it is a key intervenient in the assembly of 
the oligomerization protein platform that is the apoptosome, which is responsible, as mentioned above, 
for the autoproteolytic activation of caspase-9. The other released proteins have a variety of roles 
ranging from sequestering caspase inhibitors to the induction of morphological alterations to the 
nuclear envelope (Du et al., 2000; Schulze-bergkamen and Krammer, 2004). 
During the execution of the apoptosis process the activation of caspase effectors, like caspase-3 -6 and 
-7, regardless of the activation pathway, leads to the fracture of key architectural cellular structures 
and biochemical pathways. Namely the cytoskeleton scaffolding that ensures the 3-dimensional 
structure of the cell is one of the first key structures to be targeted during the execution phase of 
apoptosis. Molecules such as actin itself, and actin-associated proteins, like myosin, spectrins, α-
actinin, gelsolin and filamin are proteolytically destroyed causing the typical morphological hallmarks 
of apoptosis, like the acquisition of a round shape, loss of cell adherence and membrane blebbing. 
Plus, chromatin condensation is thought to be the result of nuclear lamin targeting by caspases 
(Schulze-bergkamen and Krammer, 2004; Taylor et al., 2008; Wyllie, 2010). In short the connections 
established between the myriad of regulators and pathways are the mere strings of the puppeteer that is 
the programmed cell death by apoptosis and the considerable biochemical changes that occur within 
the apoptotic cell. 
 1.3.4. Cell Division and Carcinogenesis Interplay 
The highly regulated process that cell division represents is crucial for cell turnover and tissue 
homeostasis. Cell division, or cell proliferation is separated into three sequential processes know as 
interphase, mitosis and cytokinesis. Interphase is the longest phase during cell division. It is 
characterized by very long chromatin fibbers however these tend to shorten and become thicker as 
interphase progresses. Plus it is also characterized by an increase in the overall cell size and the 
accumulation of specific macromolecules crucial for the execution and progression of the cell cycle 
that ensures the formation of two daughter cells. The accumulation of these macromolecules involves 
among others, the duplication of the genetic material, plus accumulation of RNA levels, ribosomes 
and other proteins (Weinberg, 2013). Mitosis is then preceded by the duplication of the genetic 
material, and encompasses four distinct phases: prophase, metaphase, anaphase, and telophase. In 
short mitosis is responsible for nuclear division where spindle fibbers pull the chromatids apart from 
the condensed chromosomes to each opposite pole that will result in the formation of the two daughter 
cells, that is then proceeded by segregation of the cytoplasm by cytokinesis.  
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As any other highly regulated cellular process, cell division and the overall regulation (see below) is 
prone to potential alterations and aberrant phenomena as a result of mutations. Misregulation of cell 
cycle events and the control of the commitment to cell division have been widely shown in the 
literature to play an important role in cancer onset. Compromised cell cycle regulation processes, as 
those involving the core components of the cell cycle clock, namely cyclins and cyclin dependent 
kinases (CDK), affect the proper distribution of chromosomes at the metaphase  to anaphase transition 
by the spindle-assembly checkpoint leading to overall genetic instability, aneuploidies and 
unscheduled proliferation (Malumbres and Barbacid, 2001; Malumbres and Barbacid, 2009). 
 1.3.4.1. Cell Cycle Regulation and Deregulation in Cancer 
The cell cycle is comprised of 4 distinct phases (G1, G2, S, and M) all of which are controlled by 
numerous mechanisms to ensure a correct cell division (Figure 1.8). More specifically the cell cycle is 
responsible for faithfully replicate DNA during S phase, and to ensure the equal segregation of all 
cellular components to the daughter cells including the identical chromosomal copies during the M 
phase. The remaining two phases, namely G1 and G2 are intermediate periods mainly responsible for 
an high synthesis of macromolecules and other regulators essential for cell cycle progression through 
S and M phases respectively (Malumbres and Barbacid, 2001; Sherr, 1996; Lapenna and Giordano, 
2009). 
Figure 1.8 – Illustration of the regulation of the mammalian cell cycle. Key CDK/cyclin complexes role in the distinct phases 
of the cell cycle is also displayed. Cdk4/cyclin D complexes phosphorylate Rb in mid G1, while Cdk2/cyclin A and 
Cdk2/cyclin E phosphorylate Rb at the G1 to S transition. Dephosphorylation of Rb allows binding to E2F family of 
transcription factors, forming a silencing complex restricting the progression of cell cycle, by transcription prevention of cell 
cycle control genes. Cdk2/cyclin A and Cdk1/cyclin B/A complexes and their kinase activity is essential for progression 
through S phase and entry in M phase (Adapted from ―Propidium iodide staining of cells to assess DNA cell cycle,‖ 2014). 
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Apart from the already mentioned phases there is another critical moment in the cell cycle known as 
G0, a quiescent state where most of the non-proliferating cells stand at. Furthermore progression 
through the cell cycle only occurs upon a G0―G1 transition in response to stimuli such as mitogen 
exposure and nutrient abundance (Lea et al., 2003; Schwartz and Shah, 2005). This transition is highly 
regulated and it is thought to be one of the several developed checkpoints that prevent an awry cell 
progression (Malumbres and Barbacid, 2001). In fact the transition between cell cycle phases is 
regulated by several different proteins, nonetheless the key regulatory proteins are cyclin-dependent 
kinases (CDK), the activity of which is modulated by fluctuating levels of cyclins throughout the 
progression of the cell cycle (Vermeulen et al., 2003; Schwartz and Shah, 2005). Mitogenic signalling 
leads to activation of CDK/cyclins complexes, through phosphorylation cascades such as MAPK/ERK 
pathway (Schwartz and Shah, 2005). In particular G0―G1 transition is characterized by 
phosphorylation of the retinoblastoma protein (RB1), mediated by active complexes of D-type cyclins 
with CDK4/6. Furthermore towards the end of G1 phase RB1 is phosphorylated in additional sites by 
CDK2/Cyclin E complex, breaking the tight bond with E2F transcription factor family (that 
constituted a gene silencing complex), promoting an expedite expression of S phase related genes 
(Lapenna and Giordano, 2009; Vermeulen et al., 2003; Sandal, 2002). In what is known as the 
restriction point, this event represents the point of no return in G1 in which progression through the 
cell cycle is ―automated‖ and independent of external stimuli (Lapenna and Giordano, 2009). 
Mutations in CDK–cyclin complexes, or their regulation, as well as the conformational structure of 
RB like proteins are often associated with frequent tumour phenotypes leading to uncontrolled 
proliferation and genomic instability (Malumbres and Barbacid, 2009). For instance in same cases of 
lung cancer RB alterations are found in high percentage approaching incidences of 88 % to 100 % 
(Vincenzi et al., 2006). Beyond the restriction point new intervenients come into play, namely the 
sequential formation of CDK2/cyclin A complex by complexation of both regulators, allows the 
progression through S phase into G2 phase, during which CDK2/cyclin A complex is responsible for 
the production of enzymes involved in DNA synthesis. DNA polymerases, histones and proliferating 
cell nuclear antigen (PCNA) are among the main intervenients (Lapenna and Giordano, 2009; 
Malumbres and Barbacid, 2009). Particularly in lung cancer PCNA is thought to have a specific role in 
cancer onset as it has been found to be frequently mutated (95-100%; Vincenzi et al., 2006). Towards 
the end of the interphase, during G2 phase, levels of CDK1/cyclin A experience a substantial increase 
which is thought to mediate chromosome condensation and the overall microtubule scaffolding 
dynamics responsible for spindle fibber assembly. Entry in mitosis is determined by the degradation of 
cyclin A and the formation CDK1/cyclin B which is promptly relocated into the nucleus. The final 
process occurs when CDK1 degradation by anaphase-promoting complex (APC) leads to the complete 
division into daughter cells (Lapenna and Giordano, 2009; Schwartz and Shah, 2005). 
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The activity of many cell cycle CDK and cyclins is often deregulated in many different types of cancer 
as a result from genetic and epigenetic alterations in their genes or regulators, making them a tempting 
target when it comes to cancer therapy. For instance CDK4 overexpression has been found in several 
cancer types including melanoma, sarcoma and gliomas, while cyclin D1 gene translocation is often 
associated with B-cell malignancies (Vermeulen et al., 2003). The recognition that the use of cell 
cycle intervenients as cancer targets, in particular CDKs by CDK inhibitors, could induce apoptosis, 
introduced new hope and a new possible fronts for battling cancer. 
 1.4. Principles of Cancer Therapy 
The vast cancer therapeutic procedures mainly envision to eliminate the total cancer mass, or when 
unfeasible, efforts are turned towards palliation procedures to prolong and ameliorate cancer patients 
quality of life (World Cancer Report, 2008). One key aspect to keep in mind is that treatment 
procedures greatly depend on a variety of individual factors, resulting from the individual nature of 
each cancer itself to the nature and condition of the patient and even from the socioeconomical setting. 
Conditions such as specific pathological and molecular cancer characteristics, the development stage 
and health conditions of the patient are but examples of the multitude of factors that might condition 
treatment programs (Luqmani, 2005). As so, anti-cancer therapy must be assessed for each situation, 
considering all the integrating variables at hand (Luqmani, 2005). A noteworthy realization is that 
improvements in pathology analysis, as well as in morphological, imaging and molecular 
characterization tools (e.g. magnetic resonance imaging; positron emission tomography scanners; 
mutation mapping ) have over the past decade or so, provided the means and the platforms which 
allow for the refined evaluation of such interacting variables, thus providing in that sense an avenue to 
correctly assess the most suitable treatment options (World Cancer Report, 2008). The classical 
treatment strategies mainly include surgical excision, radiotherapy, immunotherapy, endocrine therapy 
and chemotherapy, which normally are used in combination in order to eradicate the total tumour mass 
and/or diminish the possibility of invasion and metastasis. As for any other treatment program surgical 
removal as its own specific set of advantages and disadvantages and it must follow certain rules. 
Typically it is mostly applied in early detected non-invasive tumours and it involves the removal of the 
tumour as a hole plus the removal of the surrounding tissue as a precautionary measure (Baba and 
Câtoi, 2007). Similarly radiotherapy is often used in localized cancers and in conjunction with surgical 
procedures. It is based on the fact that tumoural cells are particularly more vulnerable to ionizing 
radiation than compared with healthy cells. The rationality behind it is that the use of gamma rays or 
x-rays will eventually damage important molecular regulators and pathways, directly or indirectly 
inducing DNA damage and consequently cell cycle arrest or death (World Cancer Report, 2008; Baba 
and Câtoi, 2007).  Immunotherapy on the other hand is particularly interesting as it makes use of the 
hosts defence mechanisms as an anti-cancer strategy. Perhaps the most recognised is the specific 
passive immunotherapy which involves antibodies (e.g. Cetuximab/Herceptin) against specific 
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proteins that are overexpressed in cancer cells (Doody et al., 2007; Alley et al., 2010). Endocrine 
treatment in turn deals with cancer prevention by using counteracting hormone stimulated tumours 
with antagonizing agents (Luqmani, 2005). With exception for chemotherapy, which will be addressed 
latter, these treatment programs are beyond the scope of this project and won’t be further addressed, 
although extensive literature reports present more detailed information on the subject (Baba and Câtoi, 
2007; World Cancer Report, 2008). 
Beyond the classical treatment strategies, there have been emerging new cancer therapies worth 
mentioning. These new strategies aim towards tackling classical treatment strategies’ disadvantages, 
such as lack of selectivity or efficacy that often translates to off-target effects leading to broad 
cytotoxicity and myriad of other side effects. Examples of such strategies include genetic/epigenetic 
therapy (Cross and Burmester, 2006), siRNA based approaches (Devi, 2006), nanocarriers as vehicles 
for drug delivery (Peer et al., 2007; Díaz and Vivas-Mejia, 2013), immunotherapy through microbial 
approaches (Forbes, 2010) and photodynamic therapy (Hu, 2014). Gene therapy for instance presents 
itself in a vast number of possibilities and approaches that offer multiple opportunities for battling 
cancer. In particular it can make use of genetically modified viral particles that replicate within cancer 
cells causing its oncolytic death, or perhaps in a more traditional perspective it can use gene transfer to 
introduce new genetic information into a tumoural cell or the surrounding environment to condition 
their biological aspect, and eventually corrupt tumour growth (Cross and Burmester, 2006; 
McCormick, 2001). In the most direct application tumour suppressor genes like TP53 or PTEN are 
transfected into cancer cells in which these genes are deficient (McCormick, 2001). In another 
perspective nanotechnology has over the years shown the potential to revolutionize the way cancer 
therapy is performed (R. Fernandes and Viana Baptista, 2013; Martins et al., 2014b). With the advent 
of nanotechnology, the formulation of nanocarriers as versatile vectorization platforms for drug 
delivery has been made possible (Wright, 2014). Furthermore the rational design of these nanocarriers 
coupled with a deep understanding of tumour biology and its several biochemical pathways offers 
multiple advantages over classical treatment strategies. From targeted delivery, to enhanced 
pharmacokinetic/pharmacodynamic properties and many others, the nanotechnology toolbox allows 
for a virtually endless number of possibilities to interact with cancer cells at the molecular and cellular 
level and ultimately to improve cancer therapeutics (Ferrari, 2005; Baptista, 2009). Prime examples of 
the application of nanoparticles include the conjugation of nanocarriers containing chemotherapeutic 
drugs with antibodies able to recognize overexpressed antigens at the surface of cancer cells, and the 
use of nanocarriers containing the same biological targeting abilities for imaging and diagnosis 
purposes (Peer et al., 2007). Despite the number of opportunities offered by nanotechnology, only a 
few nanocarriers have actually been approved for clinical use, due in part for the lack of knowledge 
regarding in vivo interactions and toxicological issues (Fadeel and Garcia-Bennett, 2010).  
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 All in all the stated benefits and the overall features of such alternative therapies’ programs, yet to be 
fully understood and characterized, must still be weighed in in comparison with the classical treatment 
strategies of surgery, radiotherapy and chemotherapy. In this sense chemotherapy, in spite of all the 
recent advances, is still considered as the gold standard when it comes to clinically employed cancer 
therapy (Weinberg, 2013; Chabner and Jr, 2005). 
 1.4.1. Chemotherapy: Metal Based and other Anti-Tumoural Compounds 
Chemotherapy’s principle is generally based on the use of chemical substances that target tumour cells 
in rapid proliferation, or any other hallmark of tumour cells (Martins et al., 2014a; R. Fernandes and 
Viana Baptista, 2013; Baba and Câtoi, 2007). The hyperactive growth signalling pathways that 
endows cancer cells with superior proliferative advantage over their healthy counterparts equally 
makes them more vulnerable to a wide range of drugs clinically employed, which target growth 
signalling molecules and biosynthesis processes, such as DNA replication, translation, metabolism, 
formation of mitotic spindles and others (Table 1.1) (Luqmani, 2005). A particular class of 
chemotherapeutic drugs is those based on metal compounds. The development and approval of 
cisplatin for clinical use for its anti-cancer properties in 1978 opened the world’s eyes for the potential 
of metal compounds as anti-cancer drugs (Chabner and Jr, 2005). After the success of cisplatin a boom 
of new metal compounds were screened for their anti-proliferative properties with a new spectrum of 
designs and activities. Nonetheless some questions still remain on how these compounds 
mechanistically ―work‖ under physiological conditions. While the mechanism of action is well 
established for some metal compounds such as cisplatin (DNA cross-linking), for others, it still 
remains an uncertain issue since their activity highly depends on their rational structural design 
(Gianferrara et al., 2009). The chosen metal, oxidation state, their ligands and eventually the 
physiological setting, all have a significant influence on how these compounds develop their 
therapeutic activity. Cisplatin owes its success to its high anti-cancer effectiveness, displayed in 
several solid tumours, as direct result of its own mechanism of action (Siddik, 2003). Its cytotoxicity 
occurs after crossing the cell membrane where its interaction with nucleophilic N7-sites of purine 
bases leads to the formation of intra-strand and inter-strand DNA crosslinks. Accounting for over 85 
% of all lesions  1,2-intrastrand ApG and GpG crosslinks are considered as the major forms of DNA 
adducts (Hannon, 2007; Siddik, 2003). These eventually alter and compromise the biosynthetic 
machinery leading to the activation of DNA damage response processes, culminating in the induction 
of programmed cell death (Siddik, 2003).  Conversely regarding other metal-based compounds other 
than platinum, iron, cobalt and gold compounds are prime examples currently under preclinical 
investigation since these have attracted much attention based on their modes of action different from 
that of cisplatin (Ott and Gust, 2007). Ranging from oxidative stress to wide spectrum enzymatic 
inhibition (e.g. cyclooxygenases, thioredoxin) these compounds have shown great promise in this field 
(Ott and Gust, 2007). 
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Table 1.1 – Main groups of chemotherapeutic compounds discriminating their main representatives and modes of action 
(Adapted from Baba and Câtoi, 2007). 
Regardless of the chemotherapeutic agent in question, either metal based or non-metal based, the 
potential of these substances not to act merely locally on the primary tumour but to spread 
systemically across the organism can in a sense cure an early diagnosed metastatic cancer but, at the 
same time what can be considered here as an advantage is often a major setback in clinically applied 
chemotherapeutic agents (Baba and Câtoi, 2007; Luqmani, 2005). The intrinsic broad spectrum 
activity of these compounds, as a result of a lack of specificity, frequently translates to off-target 
effects and a generalized systemic toxicity, leading to typical side effects such as loss of hair 
(alopecia), fatigue, compromised immune system, nauseas, etc (Luqmani, 2005). Furthermore as 
mentioned earlier chemotherapy’s response varies significantly, from individual to individual. Critical 
for its importance and for its part in the variability of drug responses between individuals are 
pharmacokinetic properties. Absorption, distribution, metabolism and excretion parameters vary 
substantially and influence toxicity and efficacy of medications (Garattini, 2007; Nishiyama and 
Eguchi, 2009). Plus cancers’ continuously evolving nature endows it with multiple possibilities of 
―transformation‖, meaning a parallel continuous evolution for the vast array of genetic and epigenetic 
abnormalities intrinsically characteristic of each cancer (Weinstein and Joe, 2006). The recognition 
that these alterations/abnormalities frequently vary between cancers and as well as between same 
types of cancer (Zack et al., 2013) greatly hinders the therapeutic action of existing chemotherapeutic 
regimens (Nishiyama and Eguchi, 2009), as a result of cancer’s biological heterogeneity.  
In view of these facts, the use of systemic chemotherapeutic drugs, in what has been the therapeutic 
paradigm for the past half-century, has a limiting therapeutic index, unspecific biodistribution and 
greatly increases cancer’s probability to develop multidrug resistance patterns (Crawford, 2013; Pinto 
et al., 2010). As such these fail to achieve high level consistency rates and ultimately do not to meet 
Substance group Representatives Mode of action 
Alkylating agents 
Cyclophosphamide 
Ifosfamide 
Meclorethamine 
Crosslinking of DNA chains 
Antitumour antibiotics 
Doxorubicin 
Actinomycin D 
Mitoxantrone 
Inhibition of topoisomerase II 
Intercalation 
Antimetabolites 
Vinca alkaloids 
5-Fluorouracil 
Methotrexate 
Vincristine 
Inhibition of enzymes 
Introduction of false substances in 
DNA 
Inhibition of the division spindle 
Enzymes L-Asparaginase Enzymatic cleavage of asparagine 
Unclassified chemotherapeutics 
Platinum bonds 
Hydroxyurea 
Taxol 
Crosslinking of DNA chains 
(similarly to alkylating agents) 
Destruction of enzymes 
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the current desired requirements demanded for a robust and efficient chemotherapeutic drug. 
Interestingly recent efforts to change the current norm have led to fundamental advances in the 
understanding of tumour’s mechanisms, through system biology studies, computer modelling tools 
and network theories, thus opening new ―avenues‖, not only to improve current drugs and regimens 
but also to the development of more suitable drugs and drug delivery platforms (Nishiyama and 
Eguchi, 2009). Fundamentally the paradigm shift seems to move towards combined chemotherapy 
strategies, employing new generation drugs, and newly targeted therapies. As our knowledge over 
molecular cancer biology widens and new biochemical grids are unravelled, new generation drugs 
mainly envision and aim at targeting pathways that control cellular proliferation and death (Klein et 
al., 2005). For instance the rationale behind targeting the cell cycle is based on the fact that inhibition 
of its several regulators manages to halt unrestricted tumour growth and could eventually lead to 
apoptosis. Flavopiridol in particular, an experimental drug  is best described as a CDK inhibitor and 
has in fact shown to be able to bind to CDK1, CDK2, CDK4 and CDK6, compromising their activity. 
Plus by arresting cell cycle in G1 through inhibition of CDK2/CDK4, and in G2 through inhibition 
CDK1, flavopiridol has a double action function proving to be highly efficient. Other approaches for 
targeting cell cycle arrest, in order to halt tumour growth, include the use of several other compounds 
which follow the same action principle as flavopiridol (Schwartz and Shah, 2005). Compounds such as 
bryostatins or staurosporine analogs (e.g. UCN-01), are typically involved in the induction of p21 and 
subsequent inactivation of CDK2 causing cell cycle arrest. Other secondary mechanisms of action are 
also reported (Schwartz and Shah, 2005; Klein et al., 2005). Similarly induction of programmed cell 
death can be achieved through targeting of several molecular regulators of the respective cell death 
pathways (Ricci and Zong, 2006). Interesting strategies to induce apoptosis range from activation of 
BH3-only proteins to antagonize antiapoptotic Bcl-2 family members to the abrogation of IAP binding 
to caspases by Smac/DIABLO analogs, and even stimulation of death receptor proteins such as 
TRAIL (Klein et al., 2005; Ricci and Zong, 2006). As an noteworthy example recombinant TRAIL 
developed by Genentech/Amgen, targeting DR5 and DR4 death receptors has shown that it’s 
administration not only supresses TRAIL sensitive tumours, as it doesn’t present signs of systemic 
toxicity. The relevance of such scheme comes from the fact that the induction of apoptosis through 
this extrinsic pathway, means it circumvents the absence of functional p53, and thus adding value to 
the overall therapeutic index, as the majority of cancers exhibit some sort of modification in TP53 
(Takeda et al., 2007).  
Other common strategies are usually related with cancer’s nutrient supply and often include the use of 
monoclonal antibodies (mAb) in an attempt to ―starve‖ the tumour by blocking key intermediates of 
the related pathways (Gerber, 2008). The most frequently targeted pathways include those related with 
epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF - fundamental for its role 
in angiogenesis processes), and Human Epidermal growth factor Receptor 2 (HER2), which can be 
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respectively inhibited by blockbuster mAb drugs such as cetuximab (Erbitux), bevacizumab (Avastin) 
and trastuzumab (Herceptin) (Iyer and Kadambi, 2011). 
 1.4.4.1. Gold(I) and Gold(III) Based Chemotherapeutic Compounds 
Even though the application of gold compounds dates far back in history, it was not only until the 
finding of auranofin’s potential to inhibit the growth of cultured tumour cells in vitro, that gold 
compounds were seen under a different light regarding their pharmacological properties as potential 
chemotherapeutic tools (Berners-Price and Filipovska, 2011; Lima and Rodriguez, 2011). Among the 
vast array of screened gold compounds, gold(I) and gold(III) complexes have recently attracted much 
attention owing to their substantial antiproliferative potential and to their specific modes of action 
different from that of platinum compounds (Iii, 1999; Berners-Price and Filipovska, 2011). 
Furthermore the rational design of such complexes which endow them with a large variety of ligands 
and consequently of structural geometries, virtually create an endless number of possible drug-target 
interactions reducing the probability of a unique mode of action for such complexes (Ott, 2009). 
One of the most consensual drug-target interactions is the one established between Thioredoxin 
reductase (TrxR) and the vast majority of gold(I) and gold(III) complexes alike. TrxR is a large 
homodimeric selenzoenzime, frequently overexpressed in many tumour cells and responsible for 
controlling the thioredoxin system as well as the overall redox state of the cell that is often prone to 
inhibition by some gold complexes. Recent studies have in fact shown that both complexes, exhibit a 
strong inhibitory effect over thioredoxin reductase with IC50 values ranging from 0.020 to 1.42 μM 
(Bindoli et al., 2009). The process by which TrxR is inhibited is thought to be related with the binding 
of gold compounds to the selenenylsulfide/selenolthiol redox active centre of the enzyme (Berners-
Price and Filipovska, 2011; Bindoli et al., 2009).  
The increased activity of the overall system has been correlated with tumour growth, resistance to 
chemotherapy and evasion of apoptosis. In similarly studies evidences seem to point out a relationship 
between thioredoxin reductase inhibition and the activation of apoptosis pathways in cancer cells, 
emphasizing the potential for the future development of cancer agents (Liu et al., 2011).   
Despite the increasing interest in gold complexes as potential anticancer agents few have had a direct 
application in clinical practice. Still overshadowed by poor chemical stability and concerns about 
metal and systemic toxicity (Nobili et al., 2009), extensive pharmacokinetic/pharmacodynamic and 
mechanistic studies still appear to be fundamental before effective translation into the clinics can be 
made possible. 
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 1.4.4.2. Doxorubicin 
Being at the forefront in what regards current clinical tools for cancer treatment, doxorubicin is part of 
a larger group of antineoplastic drugs called anthracycline antibiotics, in which epirubicin, and 
daunorubicin are also included (Cortés-Funes and Coronado, 2007). Since its development, 
doxorubicin has shown great anti-proliferative potential, being in fact proven to be fundamental for the 
treatment of several types of cancer and haematological malignancies, including non-Hodgkin’s and 
Hodgkin’s lymphoma, multiple myeloma, as well as lung, ovarian, gastric, thyroid, breast, sarcoma, 
and paediatric cancers (Gewirtz, 1999; Cortés-Funes and Coronado, 2007). After passive diffusion 
internalization, where concentration can be up to 500 fold higher than compared with extracellular 
levels, the plethora of processes and drug-target interactions by which doxorubicin plays its 
therapeutic effect are vast (Tacar et al., 2013; Granados-Principal et al., 2010; Gewirtz, 1999). 
Regardless the most consensual processes described according to literature falls upon two major 
mechanisms of action: DNA intercalation and generation of free radicals. 
Figure 1.9 – (Left) Doxorubicin chemical structure and (right) doxorubicin’s DNA intercalation mechanism through 
computer modelling tools (Adapted from Hannon, 2007). 
Once in the nucleus doxorubicin binds to DNA and intercalates into the base pairs of the DNA’s 
double helix, more particular in 5’ GpC sites. Plus doxorubicin presents high affinity towards 
topoisomerase II (TOPO II) resulting in the assembly of a molecular complex DNA-TOPO II 
promoting the disruption of DNA/RNA synthesis and of topoisomerase-II-mediated DNA repair 
system possibly leading to the activation of the p53 mediated apoptosis process (Thorn et al., 2012). 
On the other hand free radical generation and oxidative stress is intimately connected with four main 
processes, which include production of semiquinone, activation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidases, non-enzymatic reaction and products from the metabolism of 
doxorubicin. In short doxorubicin’s ability to induce the formation of free radicals ultimately leads to 
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the morphological and physiological modifications of biological membranes through lipid 
peroxidation, sequentially inducing cell death (Granados-Principal et al., 2010). 
 1.4.4.3. Erlotinib 
Approved for the treatment of advanced non-small cell lung adenocarcinoma, erlotinib (erlo) is a part 
of a group of EGFR tyrosine kinase inhibitors, that has shown positive results in clinical studies 
(Gridelli et al., 2007). Chemically speaking erlotinib is a quinazoline derivative and in monotherapy 
treatments has shown prolonged survival and delayed disease progression (Friess et al., 2006; Bonomi, 
2003). 
The mechanism of action is thought to be related with the abrogation of cell growth, through G0/G1 
cell cycle arrest. While particular in vitro studies have correlated the reduced cell proliferation with 
decreased levels of phosphorylated Rb  (Gridelli et al., 2007; Bonomi, 2003) supporting the evidences 
of G0/G1 cell cycle arrest, other reports have indicated increased DNA fragmentation in monotherapy 
treatments as a result of apoptosis (Bonomi, 2003). 
Other possible mechanisms of action include inhibition of angiogenic growth factor production, 
inhibition of invasion and metastasis and potentiation of antitumour activity of cytotoxic drugs and 
radiotherapy 
 1.5. Combination Chemotherapy 
Even though combination chemotherapy has been the standard in cancer treatment, recent 
comprehensive studies on tumour’s heterogeneity and the consequent unravelling of the genetic and 
molecular alterations that lead the processes of initiation to drug resistance acquisition, have provided 
the ground work for the development of new compounds with improved specificity, re-inventing 
combination regimens (Yardley, 2013). Plus the establishment of new combination regimens and their 
rational design has been recently ―built‖ upon an effort to target cancer’s typical hallmarks with 
particular focus on anti-resistance combinations (Yardley, 2013; Hanahan and Weinberg, 2011). In 
fact the rationale behind combination chemotherapy is intimately related with tumour heterogeneity 
and its implication for drug resistance, as well as with the success of combination chemotherapy, 
which greatly improves patients’ outcomes (Mayer and Janoff, 2007; Emil Frei and Eder, 2003). 
The fundamental principles considered for combination chemotherapy have been to: i) use drugs with 
non-overlapping toxicities so that each drug can be administered at near-maximal dose; ii) combine 
agents with different mechanisms of action and minimal cross-resistance in order to inhibit the 
emergence of broad spectrum drug resistance; iii) preferentially use drugs with proven activity as 
single drugs and iv) administer the combination at early stage disease (Pinto et al., 2010; Mayer and 
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Janoff, 2007; Zoli et al., 2001). In an effort to assess the potential of each combination regimen 
several mathematical modelling frameworks have been established, allowing for the characterization 
of the combined drug effect (Chou and Talalayi, 1984). The combination regimens clinically 
employed are vast and usually specific for each cancer type (―Combination Chemotherapy Regimen 
by Type of Cancer,‖ 2013). Nonetheless, those that have been screened so far were reported to be only 
additive or, at most, minimally synergistic emphasizing the need for further investigation (Yardley, 
2013). 
The main physiological advantages reported when considering combination regimens are the possible 
emergence of synergistic interactions between the compounds administered and the ability to reverse 
multidrug resistance or to delay it (Pinto et al., 2010). A myriad of compounds, like verapamil and 
several other lipid-soluble, are actually able to target and inhibit p-glycoprotein (Multi Drug 
Resistance I gene product), the efflux pump responsible for multi-drug resistance (Emil Frei and Eder, 
2003). 
 1.6. Aims and Objectives 
As the main objective the work presented intended to proceed to the full characterization of the 
cytotoxic potential and mechanisms of action of newly synthesized chlorogold compounds with 
phosphine or N,O donor ligands. In order to accomplish the established objective a series of post 
genomic techniques were performed across a library of tumoural and non-tumoural cell lines available, 
out of which two non-small cell lung  adenocarcinoma cell lines were selected for further studies. 
Parameters such as antiproliferative activity, compound selectivity, macromolecule interactions, cell 
death mechanisms, cell cycle disorders and proteomic profiles were assessed and duly characterized. It 
was also intended to pay special attention to the identification of proteins related with cell signalling, 
cell death, drug efflux pumps and DNA damage response mechanisms. As a secondary objective, it 
was expected to establish and characterize new combination therapies, employing both chlorogold 
compounds and reference chemotherapeutic drugs, such as Doxorubicin and Erlotinib. Furthermore, it 
was planned to establish two multidrug resistance cell lines as study tools for the implications of new 
combination chemotherapy programs and to perform comparisons with monotherapy treatments. 
It should be stated herein that, due to time limitations some post genomic analysis and other 
experiments were not performed in their entirety and consequently this work should be seen as a future 
on-going study platform.  
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2. Materials and Methods 
 2.1. Compounds 
All chlorogold complexes studied were synthesized in the Center of Chemistry of Instituto Superior 
Técnico by Drª. Luísa Martins. Compounds were weighed using an analytical balance and dissolved in 
dimethyl sulfoxide (DMSO) in order to obtain stock solutions at a final concentration of 10 mg ml
-1
. 
Respective stock solutions were aliquoted and stored at room temperature (≈ 25 ºC) until their further 
need for assays, as well as the remaining solid state compounds.  
The general characteristics of the complexes as well as the information needed for the preparation of 
the stock solutions are summarized in Table 2.1. 
In addition to chlorogold complexes, other classical compounds such as Cetuximab, Erlotinib and 
Doxorubicin were also used during the development of this work, in an attempt to establish new 
chemotherapeutic combination strategies.  
Table 2.1 – Molecular and structural characteristics of the studied compounds, and necessary information for preparation of 
the respective stock solutions. 
Code Molecular Formula 
Molecular Weight 
(gmol
-1
) 
Solvent 
A C6H5AuCl2NO2 389.97 DMSO 
B C3H9AuClP 308.5 DMSO 
C C27H37AuClN2 621.01 DMSO 
D C18H15AuClP 494.03 DMSO 
 
 2.2. Human Cell Lines 
Human tumour cell lines used in this work were morphologically comprised of two types; (I) adherent, 
and (II) non-adherent or in suspension. HCT116, HEPG2 and MCF7, corresponding respectively to 
colorectal carcinoma, hepatocellular carcinoma and mammary adenocarcinoma cell lines were kindly 
offered by Drª. Cecília Rodrigues from the Research Institute for Medicine and Pharmaceutical 
Sciences (iMed), from Faculdade de Farmácia of Universidade de Lisboa. All other cell lines used 
were obtained directly from ATCC (―ATCC: The Global Bioresource Center,‖ 2014). 
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Furthermore as control of cell viability assays, fibroblasts, a non-tumour foreskin derived cell line, 
was used, to evaluate and infer about compound toxicity over healthy cells. Details and cell line 
general characteristics are summarized in Table 2.2. 
Table 2.2 – Details and characteristics of human cell lines used in this work. Cell lines are discriminated by cell designation, 
type; morphology, culture properties and growth media. (DMEM - Dulbecco’s Modified Eagle Medium; FBS - Fetal Bovine 
Serum; NEA - Non-essential amino acids; Pen/Strep - Penicilin-Streptomicin). 
Cell Designation Cell Type Morphology 
Culture 
Properties 
Growth media % 
in (v/v) 
A549 
Non-small cell lung  
adenocarcinoma 
Epithelial Adherent 
DMEM; 10 % 
FBS; 1 % 
Pen/Strep 
HCT-116 
Colorectal 
carcinoma 
Epithelial Adherent 
DMEM; 10 % 
FBS; 1 % 
Pen/Strep 
H1975 
Non-small cell lung   
adenocarcinoma 
Epithelial Adherent 
RPMI; 10 % FBS; 
1 % Pen/Strep 
HEP G2 
Hepatocellular 
carcinoma 
Epithelial Adherent 
DMEM; 10 % 
FBS; 1 % 
Pen/Strep; 1 % 
NEA 
K562 
Chronic 
myelogenous 
leukemia (CML) 
Lymphoblast Suspension 
DMEM; 10 % 
FBS; 1 % 
Pen/Strep 
MCF7 
Mammary 
adenocarcinoma 
Epithelial Adherent 
DMEM; 10 % 
FBS; 1 % 
Pen/Strep 
MNT 1 Melanoma Epithelial Adherent 
DMEM; 10 % 
FBS; 1 % 
Pen/Strep 
Fibroblasts Skin (epidermis) 
Spindle-shaped/ 
bipolar and refractile 
Adherent 
DMEM; 10 % 
FBS; 1 % 
Pen/Strep; 1 % 
NEA 
Adapted from: (―ATCC: The Global Bioresource Center,‖ 2014) 
 2.3. Cell Line Handling and Maintenance 
All cell lines were cultivated and maintained in either 25 or 75 cm
2
 BD vented cell culture flasks (BD 
Biosciences, New Jersey, EUA), in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, New 
York, EUA) supplemented with 10 % (v/v) Fetal Bovine Serum (FBS; Invitrogen) and 1 % (v/v) of 
antibiotic/antimicotic Penicilin-Streptomicin (Pen–Strep + Antimicotic; Invitrogen, New York, 
EUA), with exception for H1975 cell line which was cultivated in Roswell Park Memorial Institute 
medium (RPMI; Invitrogen, New York, EUA).  
In addition, HepG2, MCF7 and Fibroblasts culture medium was further supplemented with 1 % (v/v) 
of non-essential amino acids (NEA) 100x (Sigma, St. Louis Missouri, EUA). Cell culture flasks were 
maintained in a CO2 incubator (SANYO CO2 Incubator, Electric Biomedical Co., Osaka, Japan) at 37 
ºC and at an atmosphere of 99 % (v/v) humidity and 5 % (v/v) CO2.   
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Culture cell renewal was performed approximately when an 80 % confluence was reached in the 
culture flask (Olympus CXX41inverted microscope, Tokyo, Japan) which represents the critical point 
when cells start to detach from the flask and to degenerate due to lack of nutrients, and due to contact 
inhibition. The depleted medium was removed and discarded with the aid of mechanical pump, which 
was followed by the addition of 2 mL of trypsin (TrypLE™, Invitrogen, New York, EUA) to help cell 
detachment. After an incubation period of 5 min in the CO2 incubator, trypsin activity was blocked by 
the addition of 2 mL cell medium. The cell suspension solution was transferred to 15 mL BD Falcons 
(BD Biosciences) and centrifuged at 1500 rpm for 5 min at approximately 15 ºC (Sigma 3-16K 10280, 
Tuttlingen, Germany). The supernatant was then discarded and the remaining pellet was resuspended 
in 2 mL of fresh medium. For each 75 cm
2
 cell culture flask, carrying 10 mL of fresh medium it was 
added roughly 50 μL of the cell suspension, being subsequently incubated at 37 ºC and at an 
atmosphere of 99 % (v/v) humidity and 5 % (v/v) CO2.  
 2.4. Quality Control: Mycoplasma Analysis of Cell Lines 
Cell lines were periodically evaluated for possible mycoplasma contaminations as a quality control 
check, by a Polymerase Chain Reaction (PCR) detection method. Cell samples from each cell line 
were collected by trypsinization as described in section 2.3. centrifuged at 1500 rpm for 5 min, and the 
cell pellet resuspended in Phosphate buffered saline 1x (PBS1x)(composition PBS10x: 1.37 M NaCl, 
0.027 M KCl, 0.1 M Na2HPO4, 0.018 M KH2PO4). Deoxyribonucleic Acid (DNA) extraction protocol 
was performed using the High Pure PCR Template Preparation Kit (Roche Diagnostic, Indianapolis, 
USA) following the procedure described by the manufacturer. Total DNA concentration was assessed 
using Nanodrop2000 (Thermo Scientific, Waltham, MA, USA) as well as Abs260/Abs280 and 
Abs260/Abs230 ratios as DNA purity parameters (as described by the manufacturer). A master mix 
was prepared for all samples, considering a final volume of 20 μL per reaction, containing 75mU/μL 
of Taq Red DNA Polymerase (Bioline), PCR Buffer 10x, High Specific, 1 mM from each dNTP 
(Bioline), 2 mM of magnesium chloride (MgCl2; Bioline), primers forward and reverse and the sample 
DNA at a final concentration of 20 ng/μL. The primer set used, (Table 2.2), were designed to be 
highly specific to the 16S rRNA coding region in the mycoplasma genome, thus allowing for the 
detection of the most frequent mycoplasma contaminants in cell culture environment.  
Table 2.3 – Primer set used in Mycoplasma analysis, detailing forward and reverse primer sequences, as well as the expected 
size of the specific amplicon for the 16S rRNA gene. 
Gene Primer forward (5’- 3’) Primer reverse (5´- 3’) 
Amplicon 
(bp) 
16S 
rRNA 
GAGGGCAAGTACGAGTGGCAA CTGCGCATTGCTCCGCTAACC ≈700 bp 
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Amplification of the reaction mix, was performed with the conditions described in Table 2.3, in an  
Tpersonal termocycler (Biometra GmbH, Goettingen, Germany). All amplification products were 
further separated by gel electrophoresis, in a 0.8 % (w/v) agarose gel (Thermo Scientific, Waltham, 
MA, USA), stained with 2 % (v/v) of gel red (10000x) (Biotarget, Portugal). A 110 voltage was used 
during a 50 min run, in Tris base, acetic acid and EDTA buffer 1x (TAE 1x buffer) (composition TAE 
10x: 1.7 M NaCl, 0.03 M KCl, 0.1 M Na2HPO4 and 0.01 M K2HPO4). An already know contaminated 
cell line was used as a positive control, and as negative control it was used eukaryotic cat DNA. 
Hyperladder IV (Bioline) was used as molecular weight marker. 
Table 2.4 – PCR amplification program for the 16S rRNA gene in mycoplasma detection protocol. 
Step Temperature (ºC) Time (min) Cycles 
Initial denaturation 95 ºC 5 min  
Denaturation 95 ºC 0.5 min 
30 Annealing 58 ºC 1.5 min 
Extension 72 ºC 1.5 min 
Final Extension 72 ºC 10 min  
 
 2.5. Growth Inhibition Assays 
In vitro cytotoxicity assays were performed for each cell line available and for each compound 
mentioned (sections 2.1 and 2.2), through the use the CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, Madison, USA), a colorimetric method for determining the number of 
viable cells. 
At 80 % confluence, cells were harvested and centrifuged as mentioned in section 2.3. The supernatant 
was discarded, and the cell pellet resuspended in 2 mL of medium. For growth inhibition assays, 
0.75x10
5
 cells/mL were plated into flat bottomed 96-well plates (Costar, Corning, NY) and incubated 
at 37 ºC, 99 % (v/v) humidity and 5 % (v/v) CO2. Cell density was evaluated as the total number of 
viable cells within the grids on the hemacytometer (Hirschmann, Eberstadt, Germany) using trypan 
blue exclusion method. For this procedure 350 µL of medium was pipetted to a 2 mL eppendorf 
together with 50 µL of the 2 mL cell suspension followed by 100 µL of 0.4 % (v/v) trypan blue 
solution (Sigma). The hemacytometer was loaded and examined immediately under the microscope at 
low resolution, and cell viability was determined through the following equation (1): 
           
  
 
∑                  
 
                                       (1) 
After 24 h, a range of concentrations of the specific drug in question were added (after removal of 
depleted medium), and the cells were incubated for an additional 48 h (37 ºC, 99 % humidity and 5% 
(v/v) CO2). Subsequently a reaction mix of medium, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt), and PMS (phenazine 
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methosulfate) in a ratio of 100:19:1 was added to each well and further incubated for 45 min. During 
this period, MTS is reduced into formazan by dehydrogenases present in metabolically active cells, 
which in turn is susceptible of being measured at 490 nm absorbance by Tecan Infinite F200 
Microplate Reader (Tecan, Männedorf, Switzerland), directly from the 96-well assay plate, so that the 
quantity of formazan product measured is directly proportional to the number of living cells in culture. 
The cell viability results for each concentration assayed were normalized relative to the control 
samples and obtained accordingly to the following equation (2): 
                         
                          
                         (2) 
The concentration of each compound resulting in 50 % growth inhibition (IC50) was expressed as 
percentage of the untreated controls, and calculated using Excel and GraphPad software (Graph Pad 
Software Inc., San Diego, CA, USA).  Additionally different combination therapies between 
chlorogold compounds and other classic chemotherapy drugs, such as Doxorubicin (Dox) or Erlotinib 
(Erlo), were used in an attempt to establish better chemotherapeutic strategies.   
Due to the large number of compounds and cell lines under study, initial compound screening was 
performed by testing a range of concentrations, typically between 1 and 1000 μM on all cell lines 
available, to obtain data on percentage growth inhibition and relative IC50 values. These results were 
taken into consideration for the rest of the work and further studies on the molecular mechanisms of 
anticancer activity were restricted to the most active chlorogold complexes, namely compounds B and 
D. Cell line screening and selection was performed based on the same initial results and the post-
established thesis main objective (see section 1.6 and 3.1). Non-small cell lung cancer cell lines 
(NSCLC), A549 and H1975 were thus selected for further assays. 
 2.5.1.  Combination Chemotherapy: Cell Viability Assessment 
Cell viability assessment for combination chemotherapy was proceeded in same way was described in 
section 2.5 through the use the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay 
(Promega, Madison, USA) with the exception that it was only performed in non-small cell lung cancer 
cell line, A549. Cells were seeded in 96-well plates, at 0.75x10
5
 cells/ml and incubated at 37 ºC, 99 % 
humidity and 5% CO2 (v/v) for a period of 24 h. Twenty-four hours after seeding cells were exposed 
to both compound B and doxorubicin or to compound B and erlotinib for a total exposure period of 48 
h in three distinct sequences: both compounds were administered concomitantly (I), pretreatment with 
compound B for 24 h with posterior administration of the second drug (II) and pretreatment with 
doxorubicin or erlotinib for 24 h with posterior administration of compound B (III). The 
concentrations used in each assay were based on each drug’s individual IC50 which was pre-
determined on single drug viability assays (see Appendix A and B), or in the case of doxorubicin 
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extracted from literature reports (He et al., 2011). Assays were performed in triplicate and the data 
represents the result of at least three independent experiments. 
 2.6.  Apoptotic Potential Evaluation 
 2.6.1.  Hoechst Staining 
As an early apoptotic potential evaluation assay, Hoechst 33258 fluorescent staining was performed. 
Hoechst 33258, Phenol, 4-[5-(4-methyl-1-piperazinyl)[2,4’-bi-1H-benzimidazol]-2’-yl]-, 
trihydrochloride, has a high affinity to nucleic acids (excitation and emission wavelengths of 352 and 
461 nm, respectively when bound to DNA) allowing for the identification and visualization by 
fluorescent microscopy, of early apoptotic hallmarks such as, aberrant nuclear morphology, chromatin 
condensation and apoptotic body formation (Hoechst Stains, MP21486, Invitrogen, 2005). 
Both cell lines, A549 and H1975 were collected and centrifuged as described in section 2.4. Cells 
were then seeded in flat bottomed 24-well plates (Costar, Corning, NY), at a cell density of 1x10
5
 
cell/mL and incubated at 37 ºC, 99 % (v/v) humidity and 5 % (v/v) CO2 for a period of 24 h. Prior to 
cell seeding, lamellae were sterilized with 70 % (v/v) ethanol, and further rinsed with PBS1x, being 
sequentially set at the bottom of each well. After 24 h period, the corresponding IC50 values of each 
selected compound (e.g. compound B and compound D), corresponding to their respective IC50  
values, were added to each well, considering a final volume of 400 μL, and incubated for an additional 
48 h period. Solutions were prepared using culture medium and 0.1 % (v/v) DMSO was used as 
control of the experiment.  
The culture medium of the incubated cells was then discarded and cells were rinsed three times with 
PBS1x. Cells were fixed with 400 μL solution of 4 % (v/v) paraformaldehyde diluted in PBS1x and 
incubated in the absence of light for a period of 10 min. For Hoechst staining, to each well was added 
a 400 μL solution of Hoechst 33258 (Sigma), containing 0.8 μL Hoechst 33258 (5 mg/mL) in 400 μL 
of PBS1x. An incubation of 15 min in the absence of light and at room temperature followed, and 
sequentially each well was rinsed once again three times with 400 μL PBS1x. Separately slides were 
prepared with 5 μL droplets of a glycerol solution diluted in PBS1x  (1:3 ratio). Inverted lamellae, 
containing fixed cell samples were carefully placed on top of each droplet, and thereafter visualized 
and photographed in a Olympus BX51 fluorescent microscope with an attached Olympus DP50 
(Olympus) camera. Photographs were acquired with Infarview software.    
 2.6.2.  AnnexinV-FITC and Propidium Iodide Staining 
AnnexinV-FITC (Fluorescein Isothiocyanate) and propidium iodide (PI) double staining procedure 
was carried out has a complementary study of the compound’s apoptotic potential over the selected 
cell lines, using AnnexinV-FITC Apoptosis Kit (Invitrogen). This particular assay takes advantage 
35 
 
over some of the molecular and morphological hallmarks of apoptosis. One of the earliest events of 
apoptosis consists on the translocation of the phosphatidylserine from the inner membrane leaflet to 
the outer membrane leaflet, which in turn presents high affinity for Annexin V, a Ca
2+ 
dependent 
phospholipid-binding protein, thus allowing for the detection of exposed phosphatidylserine. On the 
other hand, propidium iodide, a red-fluorescent nucleic acid binding dye, internalizes dead cells or 
cells with a compromised plasma membrane thus staining them with red fluorescence. Annexin V and 
propidium iodide staining is inherently dependent on the plasma membrane integrity, and 
consequently by taking advantage of apoptosis related molecular events involving it, it provides a 
rapid and reliable method to quantify viable cells in a cell suspension (FITC Annexin V / Dead Cell 
Apoptosis Kit with FITC annexin V and PI , for Flow Cytometry, MP 13242, Invitrogen, 2010). 
 For AnexinV-FITC and propidium iodide staining, NSCLC cell line (A549) was seeded at a cell 
density of 0.75x10
5
 cells/mL in 35 mm plates and incubated at 37 ºC, 99 % (v/v) humidity and 5 % 
(v/v) CO2. Twenty-four hours later, the medium was replaced with the medium containing the 
compounds as indicated (compound B and Dox), and further incubated for another 48 h. Chlorogold 
compound B, and Dox were used at their respective IC50 concentrations, and 0.1 % (v/v) DMSO as 
control of the experiment. Supernatant and cells were collected (supernatant was collected separately 
to BD 15 mL Falcons and cells were collected through the addition of 1 mL of trypsin and incubation 
at 37 ºC, 99 % (v/v) humidity and 5 % (v/v) CO2 for 5 min), and centrifuged at 1500 rpm for 5 min. 
Supernatants were discarded and the cell pellets were rinsed three times with 1 mL PBS1x intercalated 
with 5 min centrifugations at 1500 rpm. Afterwards 100 μL of annexin Binding Buffer 1x was added 
to all cell samples. Additionally 5 μL of annexin V and 2 μL of propidium iodide were added to the 
samples, followed by an incubation of 15 min in the absence of light and at room temperature. 
Sequentially another 400 μL of Anexin Binding Buffer 1x were added, and 500 μL of PBS 1x, to 
make up to 1 mL solution to each sample.  After staining cell populations with FITC annexin V and PI 
in the in the respective buffer, apoptotic cells show green fluorescence, dead cells show red and live 
cells show little or no fluorescence (FITC Annexin V / Dead Cell Apoptosis Kit with FITC annexin V 
and PI , for Flow Cytometry, MP 13242, Invitrogen, 2010). 
Cell samples were analyzed by flow cytometry on an Attune® Acoustic Focusing Flow Cytometer 
(Life Technologies, Carlsbad, California), through the acquisition of at least 10000 events for each 
experimental condition. 
 2.7.  DNA Interaction Studies 
 2.7.1.  UV/Vis Spectrophotometric Analysis 
Many metal based chemotherapeutic drugs are known to interact and influence the overall molecular 
structure of the DNA molecule, often comprehending their main mechanisms of action by which they 
36 
 
exert their therapeutic effects. UV/Vis spectrophotometry assays allowed to draw conclusions about 
the drug interaction with DNA (Shahabadi et al., 2011). Assays were performed using Calf Thymus-
DNA (CT-DNA; Invitrogen), which it’s concentrations were determined by NanoDrop reading at 260 
nm, considering both the DNA molar extinction coefficient (6600 M
-1
 cm
-1
) and lambert beer's law 
(Equation (3)): 
         (3) 
Where A is the absorbance measured at 260 nm, ε the molar extinction coefficient in M
-1
 cm
-1
, l the 
optical path in cm, and c the sample concentration in molL
-1
 (Ahmadi, 2011; Gallego et al., 2011). 
The UV-Vis spectra for DNA with chlorogold compounds interactions were obtained using an 
Evolution 300 UV-Vis spectrophotometer (Thermo Scientific). Absorption titration experiments were 
carried out by keeping the concentration of DNA constant (20 μM) while varying the complex 
concentration from 1 to 100 μM. Samples were prepared in 5 mM Tris-HCl (Merck), 50 mM NaCl 
(Panreac), pH 7 buffer, and were incubated at 37 °C for 24 h. DMSO was used as reference solution in 
the same concentrations as that used for samples. 
Maximum absorbance values were corrected by the subtraction of the respective values obtained for 
the reference samples (DMSO) in the same wavelength and fitted in the following equation (4) in 
order to obtain intrinsic binding constant, Kb, of the respective compounds: 
[   ]
        
  
[   ]
       
 
 
         
 (4) 
where εa, εf , and εb are the apparent, free and bound complex extinction coefficients, respectively. In 
particular, εf was determined by a calibration curve of the isolated metal complex in aqueous solution; 
following the Beer’s law, εa was determined as the ratio between the measured absorbance and the 
chlorogold complexes concentration. The inability to obtain tangible and reproducible results through 
this assay, possibly due to a lack of compound stability in the mentioned buffer, led to its discontinuity 
and no significant results are shown for this particular assay (see appendix C). 
 2.7.2. DNA cleavage assay 
DNA interaction studies were further evaluated through DNA cleavage assays. In these assays double-
stranded closed circular high copy plasmid pUC18 DNA (Fermentas, Maryland, EUA) concentration 
was maintained constant (10 ng/μL), while compound concentration varied differently from each 
chlorogold compound, namely compound B concentrations varied from 10 μM  to 200 μM , whereas 
compound D concentrations varied from 10 μM  to 300 μM . 
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10 ng/μL of pUC18 were incubated either in the presence of the respective compound concentrations, 
or in the presence of 0.62 % or 2.23 % (v/v) of DMSO  as reference solutions (compound B and D 
respectively) considering a total reaction volume of 20 μL. Incubation was performed in 5 mM Tris-
HCl, 50 mM NaCl buffer (pH 7) for a period of at least 24 h at 37 ºC. After incubation at 37°C, a 20 
μL aliquot of each reaction was mixed with 4 μL of 6x loading dye (Fermentas, Maryland, EUA) and 
electrophoresed on 0.7 % (w/v) agarose gel for 2 h at 70 Volts. As a molecular weight marker λ 
DNA/HindIII (Fermentas, Maryland, EUA) was used. Sequentially the gel was stained with an 
ethidium bromide solution (Invitrogen) (0.05 μg/mL in 100 mL of distilled water) for 30 min with 
agitation. Excess of ethidium bromide was rinsed with 100 mL of distilled water. Gel results were 
visualized using Molecular Imager® Gel Doc™ XR+ System with Image Lab™ Software (BioRad, 
Berkley, California) and image acquisition was obtained with GelDoc software. Data treatment was 
performed using GelAnalyzer software and as a result of three independent assays. 
 2.8.  Cell Cycle Progression Assay 
The tightly regulated cell cycle progression, with its numerous checkpoints, composes an optimal bio-
indicator of cell health, as any deviation or delay in its distinct phases may point out deficient 
processes and pathways as a result of an extrinsic (or intrinsic) input such as chemotherapeutic drugs 
(Malumbres and Barbacid, 2009). Cell cycle alterations are consequently a good indicator of 
chemotherapeutic drug’s ability to target cell cycle intervenients, ultimately leading to cell cycle arrest 
or apoptosis. For cell cycle progression analysis, NSCLC cell line (A549) was seeded in 25 cm
2
 cell 
culture flasks, at a cell density of 2x10
5
 cells/mL and incubated at 37 ºC, 99 % (v/v) humidity and 5 % 
(v/v) CO2. Thymidine, a commonly used S-phase blocker in cell cycle progression studies was used to 
slow down and arrest cells in S-phase progression. For a clear synchronization at early S-phase a 
double thymidine block procedure described by Borralho and coworkers (2009) was performed.  
After 8 h of cell seeding, the first thymidine block was performed by the addition of 2 mM thymidine 
(Sigma) in culture medium. Culture flasks were then incubated for a further 14 h at 37 ºC, 99 % (v/v) 
humidity and 5 % (v/v) CO2. Afterwards depleted medium was removed and culture flasks were 
incubated without thymidine for an additional 10 h, at the end of which it was added 2 mM thymidine; 
followed by incubation at 37 ºC, 99 % (v/v) humidity and 5 % (v/v) CO2 for 14 h followed. At the end 
of the thymidine block procedure, depleted medium containing thymidine was removed and replaced 
either by chlorogold compound solutions and/or doxorubicin, at their respective IC50 concentrations, 
or by 0.1 % (v/v) DMSO (control), diluted in fresh medium. Exposure times to the respective 
compounds were established to be 3, 6 and 9 h. 
Cell samples were collected by trypsinization as described in section 2.4 in 15 mL falcons, and 
centrifuged at 2000 rpm for 5 min at 4 ºC. Supernatant was removed and the cell pellet was 
38 
 
resuspended in cold PBS 1x and centrifuged at 2000 rpm once more. Supernatant was discarded and 
the remaining sediments were resuspended in 1 mL PBS1x followed by fixation with a 1 mL of an 80 
% (v/v) ethanol solution previously made and stored at -20 ºC. The ethanol solution was added 
carefully and progressively into the cell suspension, and with gentle agitation in vortex. Cell samples 
were then maintained in ice for a period of 30 min to improve fixation efficiency, after which samples 
were stored at 4 ºC for at least 18 h prior to analysis. As a synchronization control, cells from a 
separate culture flask were immediately collected and fixated after the end of the thymidine block 
procedure, and were considered as the initial time point.   
Falcons were centrifuged at 2000 rpm for 5 min at 4 ºC, and the supernatant was discarded, The 
remaining cell pellet was resuspended in 1 mL of a propidium iodide solution (50 µg/mL propidium 
iodide, 200 mL distilled water, 0.1 % sodium citrate, 0.02 ng/mL RNAse, 0.20 % Nonidet P-40; 
pH=7) and incubated at room temperature for 30 min. Cell cycle progression analysis was performed 
in a Attune® Acoustic Focusing Flow Cytometer through the acquisition of at least 10000 events per 
sample. Data treatment was carried out using Excel software as the result of three independent assays. 
 2.9.  Proteomic Studies: Two-dimensional (2-D) Gel Electrophoresis 
 2.9.1.  Sample Preparation, and Compound Exposure 
Proteomic studies were carried out in NSCLC A549 and HCT-116 cell lines exposed to DMSO. Cell 
lines were collected by trypsinization as described in section 2.4 and centrifuged at 1500 rpm for 5 
min. Cells were then resuspended in medium and seeded in 25 cm
2
 culture flasks at a cell density of 
2x10
5
 cell/mL, and incubated at 37 ºC, 99 % (v/v) humidity and 5 % (v/v) CO2  for a period of 24 h. 
Next cell medium was discarded and replaced by 0.1 % (v/v) DMSO, both diluted in fresh medium. 
Time exposure to DMSO was established to be 48 h. Culture flasks were incubated in the same 
conditions described above. 
After 48 h incubation period cells were collected by trypsinization and centrifuged at 2500 rpm for 5 
min and at 4 ºC. Cell sediments were rinsed three times with PBS1x, and centrifuged in between, in 
the same conditions as mentioned above. 
 2.9.2.  Whole Protein Extraction: Ultrasonication 
For whole protein extraction, previously harvested cells were resuspended in a cell lysis solution (100 
μL per 4x10
6
 cells/mL) comprised of NaCl-Tris-EDTA buffer (150 mM NaCl; 50 mM Tris, pH=8; 5 
mM EDTA), phosphatase inhibitors 1x (PhosStop, Roche), protease inhibitors 1x (cOmplete ULTRA 
Tablets, Mini, EASYpack, Roche, Basel, Switzerland), 0.1 % (w/v) dithiothreitol (DTT) (AMRESCO, 
USA), 1 mM of phenylmethylsulfonyl fluoride (PMSF) (Sigma), 2 % (w/v) Nonidet P-40 (Thermo 
Scientific, Massachusetts, EUA). Sequentially cell suspensions were submitted to ultrasonication 
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protein extraction protocol (Table 2.4), by which cells are disrupted by high-frequency sound waves 
that generate low pressure regions, ultimately leading to cell membrane rupture and protein 
extravasation.  
Table 2.5 – Ultrasonication protein extraction protocol. 
Cycles Bursts Output (%) 
3 5 60 
5 10 70 
15 20 70 
* Samples were maintained in ice for 30 seconds between cycles to avoid overheating and protein loss due to shear forces. 
 2.9.3.  Whole Protein Precipitation and Purification: 2-D Clean-Up Kit 
Cell lysates were centrifuged 14000 xg for 15 min and supernatants were recovered and stored at -80 
ºC. For whole protein precipitation and purification 2-D Clean-Up Kit (GE Healthcare, Little Chalfont, 
United Kingdom) was used accordingly with manufacturer protocol except for wash additive and wash 
buffer step were cell lysates were incubated overnight at -20 ºC. Plus centrifugations were performed 
for 15 min instead of the indicated 10 min.  
Following centrifugation, 100 μL of re-hydration buffer (7 M urea (BDH Prolabo, VWR 
International), 2 M Tiourea (Merck, Frankfurt, Germany), 2 % (w/v) (3-[(3-
Cholamidopropyl)dimethylammonio]-1 propanesulfonate) (CHAPS) (GE Healthcare), phosphatase 
inhibitors 1x, protease inhibitors 1x, bromophenol blue (Merck), 1 μL 10 % (w/v) DTT and 1μL of 
100 mM PMSF) was used to resuspend the whole protein extract. After 2 h incubation at room 
temperature whole protein extract was centrifuged at 14000 xg for 15 min and the resulting 
supernatant recovered. Selective protein precipitation is greatly improved through the employment of 
such reagents while circumventing interfering sources such as salts, nucleic acids, lipids, and phenolic 
compounds by promoting their suspension in solution, consequently improving 2-D gel quality results 
(GE Healthcare 2-D Clean-Up Kit, 2009). 
 2.9.4.  Whole Protein Quantification: Pierce Reagent 660 nm 
Protein quantification was carried out by employing Pierce Protein Assay Kit (ThermoScientific). 
Prior to protein quantification a calibration curve was established using know standard Bovine Serum 
Albumin (BSA) solutions, with concentrations ranging from 0 to 500 μg/mL. To 50 μL of replicate 
standard solution it was added 750 μL of protein assay reagent (1:15 ratio) and the mixture gently 
stirred by vortex. For unknown sample solutions, 5 μL of whole protein extract was added to 45 μL of 
deionized water, plus 750 μL of protein assay reagent. Samples were incubated at room temperature 
for 5 min prior to spectrophotometer reading at 660nm. 
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 2.9.5.  2-D Gel Electrophoresis: Isoelectric Focusing 
2-D gel electrophoresis first dimension, isoelectric focusing (IEF), was performed by in-gel 
rehydration using the Ettan IPGphor3 IEF System (GE Healthcare). Sample loading into sample cups 
was carried out by uniformly distributing  200 μg of whole protein extract, resuspended in 125 μL of 
rehydration solution supplemented with 0.5 % Immobilized pH gradient (IPG) (GE Healthcare) and 
0.5 % de destreak (GE Healthcare), into each 7 cm IPG strip holder (GE Healthcare). Immediately 
after, a 7 cm long Immobiline DryStrip pH 3-10 NL (GE Healthcare) was placed over the sample and 
special attention was taken to ensure that no bubbles were formed between the gel and the sample. 
Furthermore 750 μL of Drystrip Cover Fluid (GE Healthcare) were added over the strip to ensure full 
immersion. A 5 step program, displayed in Table 2.5 was used for IEF. 
Table 2.6 –2-D gel electrophoresis IEF five step program. 
Steps Voltage (V) Time (h) Temperature (°C) 
1 30 14 20 
2 100 0.5 20 
3 500 0.5 20 
4 1000 0.5 20 
5 5000 1 20 
 
 2.9.6.  2-D Gel Electrophoresis: SDS-PAGE 
Immediately after IEF and prior to the second-dimension run, immobiline drystrip gel equilibration 
was performed in order to promote saturation with the Sodium dodecyl sulfate (SDS) buffer system 
required for second-dimension separation. A 5 mL solution comprised of 70 mM Tris-HCl pH 8.8, 6M 
Urea, 30 % (v/v) glycerol, 2 % (w/v) SDS and 1 % (w/v) DTT (GE Healthcare) was used as a first 
equilibration step for 15 min, followed by a second supplemented with 2.5 % (w/v) iodoacetamide 
(GE Healthcare) for another 15 min. 
For the second-dimension run a SDS-PAGE Mini-PROTEAN® 3 System was used.  Plus a lab-cast 12 
% (v/v) polyacrylamide gel was also prepared, comprised of 4 mL of a 30 % (w/v) acrylamide/bis-
acrylamide mix, 3.5 mL of deionized water, 2.5 mL of Tris-HCl buffer (Merck) 1.5 M pH 8.8, 75 μL 
of a 10 % (v/v) ammonium persulfate (APS) (Biorad, California, USA) and 10 μL of 
tetramethylethylenediamine (TEMED) (Sigma). After gel polymerization (approximately 30 min) IPG 
strips were put on top of each gel and sealed with an agarose solution (0.5 % (w/v) agarose diluted in 
running buffer (3.79 g/L Tris, 18 g/L glycine, 1.25 g/L SDS, and evidences of bromophenol blue).  
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Initially electrophoresis run was performed at a Voltage of 30 V, for roughly 30 min in order to 
promote protein transfer from IPG strips to SDS-polyacrylamide gel, and in a second step for 150 V 
for 90 min until no evidences of bromophenol blue was left in the gel 
 2.9.7.  Detection and Digital Imaging 
Gel staining was performed using 3 PhasTGelTM Blue R tablets (Coomassie R350) (GE Healthcare) 
diluted in 1 L, 10 % (v/v) acetic acid. The gel containing solution was further heated in the microwave 
oven for 2 min at 900 watts (W), and the process was repeated every 20 min three times. Microwave 
heated deionized water (2 min at 900 watts) was used for rinsing the gel until appropriate contrast was 
obtained for protein spot detection. Images of the 2-DE gels were acquired through Magic Scan 
software in Tiff and Lab Scan format, and protein spot analysis was carried out by Melanie 7.0 
software (GeneBio, Genebra, Switzerland). Protein spot comparison was conducted between gels in 
order to evaluate abundance level variation, considering the different analyzed conditions. Abundance 
level variation was calculated through the ratio between intensity of each sample spot and its 
homologous spot in the control gel. Abundance levels ≤ 0.7 and ≥ 1.5 were considered significant. 
 2.10. Multidrug Resistance Induction 
Multi-drug resistance acquisition is still largely unexplored and somewhat controversial; thusly cell 
line models offer a sturdy in vitro platform to study and understand drug resistant tumour cells and 
associated molecular patterns and pathways. HCT-116 and A549 cell lines, long term exposure to 
increasing concentrations of Doxorubicin allowed to establish a series of descendent subcultures that 
were significantly more resistant to this particular drug. Drug resistance induction was established in 
vitro in a step wise increase in doxorubicin concentration in culture medium. HCT-116 and A549 
original cell lines were subcultered as described in section 2.3, and were seeded at approximately 20 % 
confluence, in independent 25 cm
2
 culture flasks for drug resistance induction. Drug resistance culture 
flasks were incubated at 37 ºC, 99 % (v/v) humidity and 5 % (v/v) CO2 for 24 h at the end of which, 
cell lines were exposed to a pre-determined doxorubicin concentration that varied between cell lines. 
HCT-116 cell line was submitted to a step wise increase in doxorubicin concentration that ranged from 
0.001 μg/mL to 0.5 μg/mL, while A549 cell lined doxorubicin concentration ranged from 0.0058 
μg/mL to 0.029 μg/mL. Cell lines were maintained in the same concentration for 5 subcultures to 
allow cells to adapt to drug concentration and to develop resistance molecular patterns. A total of 15 
out of 30 planed subcultures were carried out. The total number of subcultures (30) under drug 
exposure was considered, accordingly to literature reports, to be enough to induce a resistance 
phenotype. 
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3. Results and Discusion 
 3.1. Cytotoxic Potential Evaluation  
The antiproliferative potential was evaluated through assessment of the cytotoxicity of chlorogold 
compounds B and D in non-small cell lung (A549; H1975), human colorectal (HCT116), 
hepatocellular (HepG2), breast (MCF-7) and melonotic (MNT-1) carcinoma cell lines as well as in 
chronic myelogenous leukaemia (K562) and human normal fibroblasts. After a 48 h exposure period 
to chlorogold compounds B and D, spectrophotometric quantification of the amount of formazan, 
resulting from MTS reduction by mitochondrial dehydrogenases of metabolically active cells, using 
the CellTiter 96 ® AQueous non-radioactive cell proliferation assay, allowed to establish a correlation 
between the colour intensity of the formazan dye and the number of viable cells (Wang et al., 2010; 
Riss et al., 2013). From the results obtained, it was possible to determine important pharmacological 
parameters, namely the absolute and the relative IC50 values (among other parameters), which prove 
themselves fundamental for the validation and characterization of the compounds, as well as for the 
understanding of which mechanistic studies, in vitro and in vivo should be performed to assess 
potential therapeutic applications before effective translation into the clinics is made possible 
(McGowan et al., 2011). When considering the concepts of absolute and the relative IC50 values this 
are somewhat controversial and important guidelines should be followed (Sebaugh, 2010). While the 
absolute IC50
 
corresponds to the concentration that represents the halfway point between 100 % and 0 
% viability, the relative IC50  is the concentration required to bring the dose-response curve down to the 
point halfway between the top and bottom plateaus of the curve. The full quantification of a drug’s 
potency in relation to its target is logically unfeasible when applying the concept of absolute IC50 as 
some drugs often develop their therapeutic action in a non-dose dependent way. In this sense the 
concept of an absolute IC50 is not standard, and many find it not to be useful. The concept of relative 
IC50 on the other hand is considered to be the most common definition in accordance with 
pharmacological analysis (Neubig et al., 2003) and it will be considered the norm hereon forward. All 
values were calculated from dose-response curves resorting to GraphPad software. 
Observation of the data shown in Table 3.1 outlines that both compounds, B and D induced a varying 
but substantial degree of cytoxicity in all cell lines screened, yielding IC50 values in the 10
-6
 to 10
-5
 M 
range after continuous exposure to various concentrations for a period of 48 h. Furthermore dose-
response curves, showed in Appendix A, highlight the ability of the compounds to inhibit cell 
proliferation in a dose-dependent manner. Relative IC50 are displayed in upper right corner of each 
chart, which in turn are specific for each compound and for each cell line. 
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Table 3.1 – IC50 values for chlorogold compounds B and D, in non-small cell lung (A549; H197), human colorectal (HCT-
116), hepatocellular (HepG2), breast (MCF-7) and melonotic (MNT-1) carcinoma cell lines as well as on chronic 
myelogenous leukemia (K562) and human fibroblasts. Data values are referent to those reported in Appendix A, and are 
represented as means of at least three independent experiments. 
 
Among all the tested cell lines, compound B and D elicited the strongest inhibitory effect on the 
proliferation on H1975 NSCLC cell line, exhibiting IC50 values of 3.36 and 5.43 μM respectively. On 
the other hand H1975 NSCLC cell line counterpart, A549, displayed values of 44.40 and 30.09 μM 
respectively in what was the weakest antiproliferative effect in all cell lines available. Indeed 
compound B and D’s activity on H1975 is approximately 13.2 and 5.5 times higher than when 
compared with A549, clearly evidencing not only different mechanisms of action differing between 
cell lines but also consequently different susceptibilities. Of relevance from the remaining tumoural 
cell lines, HCT-116 and HEP G2 exhibited very similar responses for both compounds and in between 
cell lines (HCT-116 - 9.51; 9.02 μM / HEP G2 – 9.97; 9.79 μM for compound B and D respectively). 
Moreover MCF-7 and MNT-1 displayed the second highest IC50 values for both compounds, after 
A549 (MCF-7 – 11.65; 13.06 μM / MNT-1 – 17.88; 11.64 μM for compound B and D respectively). A 
relevant particularity when observing Table 3.1 is the variability of distinct tumoural cell line response 
when exposed to the same compounds. This simultaneously puts in perspective the plethora of 
morphological and molecular differences typical of each cancer cell line, as result of differentiation 
and mutational processes, and the different possible drug-target interactions by which the chlorogold 
compounds may ―take advantage of‖ to play their cytotoxicity. 
In particular viability rates obtained for both A549 and H1975 are evidence in Figure 3.1 and 3.2 
respectively, after a 48 h exposure treatment with compound B and D. A closer analysis in both cell 
lines allows the observation of a gradual decrease in cell viability as compound concentrations rose.  
The effect is particularly more evident for concentrations above 20 μM in A549 and for concentrations 
roughly above 2.5 μM in H1975, for both compounds. Taking into consideration doxorubicin´s IC50 
values for the same cell lines, namely 9.20 μM for A549 and 0.066 μM for H1975, the (He et al., 
2011; Brechbuhl et al., 2013), chlorogold compounds are unable to achieve growth inhibition in that 
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order of magnitude. Nonetheless the results displayed either in Table 3.1 or in Figures 3.1 and 3.2 
suggest that chlorogold compounds confer antiproliferative properties in vitro for both tumoural cell 
lines, however the drug concentrations necessary to inhibit cell growth are substantially higher than 
those of renowned chemotherapeutic drugs such as doxorubicin or cisplatin (He et al., 2011). Despite 
these differences the chlorogold compounds in question seem to target the proliferative nature of 
cancer, one of the main basal cell functions. Since basal cell functions are always supported by 
specialized pathways, chlorogold compounds most likely affect specific regulators opening new 
possibilities for potential novel therapies in cancer treatment. However prudence must be taken into 
consideration as results in vitro may not be fully depictured in the same way as in vivo. Fundamental 
pharmacokinetic properties such as rates of absorption, biotransformation, distribution and excretion, 
that influences compound exposure in vivo can’t be adequately represented in in vitro assays (Holohan 
et al., 2013). 
 
Figure 3.1 – Dose dependent cytotoxicity of chlorogold compounds, B (left) and D (right), on non-small cell lung 
adenocarcinoma cell line (A549). The respective relative IC50 of each compound is displayed in the upper right corner of 
each chart. The data are represented as means ± SEM of at least three independent experiments; *p < 0.05, as compared with 
the control group. Cell viability values were normalized in relation to the control group without compounds (only DMSO). 
Figure 3.2 – Dose dependent cytotoxicity of chlorogold compounds, B (left) and D (right), on non-small cell lung 
adenocarcinoma cell line (H1975). The respective relative IC50 of each compound is displayed in the upper right corner of 
each chart. The data are represented as means ± SEM of at least three independent experiments; *p < 0.05, as compared with 
the control group. Cell viability values were normalized in relation to the control group without compounds (only DMSO). 
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Figure 3.3 – Dose dependent cytotoxicity of chlorogold compounds, B (left) and D (right), on fibroblast cell line. The 
respective relative IC50 of each compound is displayed in the upper right corner of each chart. The data are represented as 
means ± SEM of at least two independent experiments; *p < 0.05, as compared with the control group. Cell viability values 
were normalized in relation to the control group without compounds (only DMSO). 
Information on the relative toxicity spectrum on non-tumoural cells was also assessed. In this sense 
investigation was proceeded towards determination of the effects of chlorogold compounds B and D, 
on cell growth and cell survival in a fibroblast healthy cell line. Analysis of Figure 3.3 evidences a 
substantial dose-dependent cytotoxicity observed for both compound B and D, being significant for 
concentrations ≥ 20 μM for compound B and for concentrations ≥ 50 μM for compound D (p < 0.05). 
The IC50 values obtained for both compounds are actually lower than when compared with A549 cell 
line (5.7 and 1.6 fold lower), meaning that lower concentrations tend to induce more cell death in 
fibroblast healthy cell line than in A549. The IC50 value comparison for H1975 is not as dramatic as to 
its counterpart; nonetheless results only evidence a slightly higher IC50 value for compound B and D in 
fibroblasts comparing with H1975 values (Table 3.1).  
Considering extrapolation of these results into a hypothetical clinical translation, as potential 
chemotherapeutic agents of NSCLC, would have to be done with diligences as these compounds 
reveal substantial toxicity towards healthy cells at their respective IC50 values for the treatment of 
NSCLCs. Ideally chlorogold compounds should have pertained a higher ―predisposition‖ to target 
tumour cell lines than healthy cell lines, this being noticeable by a far higher IC50 values in fibroblasts 
cell line. In these sense one possibility to circumvent broad toxicity, would be to consider these 
chlorogold compounds in targeted therapies for NSCLC, such as antibody drug conjugates or 
nanocarriers as drug delivery platforms (Martins et al., 2014b; R. Fernandes and Viana Baptista, 2013; 
Iyer and Kadambi, 2011; Singh and Lillard, 2009). Nonetheless in view of chlorogold compound’s 
potency against H1975 and the weaker results in A549, both cell lines were selected for further assays 
in an attempt to unravel the governing mechanisms of action of each compound that determine the 
different therapeutic responses in each cell line. 
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 3.2. Combination Chemotherapy and Implications in NSCLC Treatment 
The inability of current chemotherapeutic single agents to effectively manage non-small cell lung 
cancer death in first world countries has halted the progress in the treatment of this disease. Reaching 
this plateau in the development of effective strategies, as led to experimentation with different 
combination processes in order to tackle such problem (Van Schaeybroeck et al., 2006). Cell viability 
assay in NSCLC A549 cell line in response to compound B and doxorubicin in combination therapy 
(Figure 3.4), was performed in order to assess its potential as a novel possible combination therapy for 
this disease.  
Figure 3.4 – Cell viability in NSCLC A549 cell line in response to compound B and doxorubicin in combination therapy. 
Combination strategies’ (1º Dox_B; 1º B_Dox; B&Dox) effectiveness was compared to single agent (SA) treatments 
(Dox_SA; B_SA). All strategies resorted to the IC50 values of each compound (see section 3.1). The data are represented as 
means ± SEM of at least three independent experiments; *p < 0.05, as compared with the control group. Cell viability values 
were normalized in relation to the control group without compounds (only DMSO). 
A broad analysis of Figure 3.4 evidences that not all combination strategies employed using these 
compounds exhibited a considerable cytotoxicity in comparison with the single agent (SA) treatments 
of doxorubicin (Dox_SA) and compound B (B_SA) at their respective IC50 values. A closer look 
allows to observe that the first treatment strategy, pretreatment with doxorubicin for 24 h with 
posterior administration of compound B for 24 h (1º Dox_B), decreases the loss in cell viability 
compared to single agent treatments (e.g. 45 % to 51 % of cell viability increase compared to 
doxorubicin). This result might give an indication of possible antagonism when employing such 
strategy. Pretreatment with compound B for 24 h with posterior administration of doxorubicin for 24 h 
(1º B_Dox) and/or the administration of both compounds concomitantly for 48 h (B&Dox), have 
evidenced a reduction in cell viability compared to single agent treatments (cell viability of 33.8 and 
22.3 % respectively). In fact the administration strategies, 1º B_Dox and B&Dox are approximately 
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1.5 and 2.3 fold more cytotoxic compared to Dox_SA, respectively. In contrast with the first treatment 
strategy (1º Dox_B) pretreatment with compound B for 24 h in 1º B_Dox strategy, has apparently 
enhanced doxorubicin-induced cytotoxicity in A549 cell line, possibly by cellular redox homeostasis 
impairment. Compound B administration could eventually augment doxorubicin’s main mechanisms 
of action, namely DNA biosynthesis inhibition and formation of ROS (Thorn et al., 2012). In addition, 
simultaneous administration further attests for this cooperative effect, visible by an even lower cellular 
viability value (22.2 % in comparison with 45.2 % for Doxorubicin alone). Albeit none of the results 
are statistically significant, these provide initial evidences as for their possible mechanisms action and 
more importantly the pharmacodynamic properties between doxorubicin and compound B. Further 
exploitation and adjustments on drug-ratio concentrations could strengthen the full therapeutic 
potential of this drug combination (Mayer and Janoff, 2007) lowering the amount of compounds/drugs 
needed for the same cytotoxic effect and providing for novel therapeutic strategies and ―avenues‖ in 
cancer treatment. 
In parallel with the above mentioned combination study, two other combinations were tested and duly 
analysed. Particularly cell viability assay in NSCLC A549 cell line, in response to the combination of 
erlotinib and compound B, or erlotinib and doxorubicin were assessed as potential tools for 
chemotherapy (Figure 3.5). Taking into consideration that as much as 80 % of all NSCLC patients 
display EGFR overexpression (Van Schaeybroeck et al., 2006), selection of erlotinib as the 
preeminent drug in these strategies was a seemingly logical approach and a key intermediate for the 
success of the established strategies. In fact erlotinib’s application in clinical research has provided 
substantial  
Figure 3.5 – Cell viability in NSCLC A549 cell line in response to erlotinib and compound B (Left) and erlotinib plus 
doxorubicin (Right) in combination therapy. Combination strategies’ (1º Erlo_B; 1º B_Erlo; Erlo&B; Erlo_Dox; Dox_Erlo; 
Erlo&Dox) effectiveness was compared to single agent (SA) treatments (Dox_SA; Erlo_SA; B_SA). All strategies resorted 
to the IC50 values of each compound (see section 3.1). The data are represented as means ± SEM of at least three independent 
experiments; *p < 0.05, as compared with the control group. Cell viability values were normalized in relation to the control 
group without compounds (only DMSO). 
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positive results in several areas, such as in adjuvant treatment, in the first-line therapy of advanced 
disease and in combination with cytotoxic treatments (Gridelli et al., 2007). The success of phase I/II 
clinical trials combining erlotinib and bevacizumab, or sorafenib and erlotinib on constraining and 
abrogating antiproliferative growth on several NSCLC patients, has raised awareness and interest in 
the potentiality of other combinations employing erlotinib and other molecular target drugs (Gridelli et 
al., 2007). 
Examination of cell viability assay in NSCLC A549 cell line in response to erlotinib and compound B 
(left chart-Figure 3.5) puts in evidence the feasibility of this combination of compounds, as all the 
strategies employed and illustrated (1º Erlo_B; 1º B_Erlo; Erlo&B), indicate a substantial reduction in 
cell proliferation in comparison single agent treatments (Dox_SA; Erlo_SA; B_SA). A more thorough 
analysis, reveals that pretreatment with erlotinib for 24 h with posterior administration of compound B 
for another 24 h (1º Erlo_B) presents a total cell viability count in the order of 15.6 %, while 
pretreatment with compound B for 24 h with posterior administration of erlotinib (1º B_Erlo) a cell 
viability count in the order of 29.9 %. Similarly, simultaneous administration of both compounds 
(Erlo&B) exhibited a cell viability of 17.3 %. In comparison with Dox_SA (45.2 % cell viability) 
these values represent a reduction in cell viability, in an order of magnitude of 2.9, 1.7 and 2.6 fold, 
respectively. Of these strategies only 1º Erlo_B and Erlo&B are statistically significant in comparison 
with SA treatments, which seems to be in accordance with what is published in literature regarding the 
active role of erlotinib in combination therapies and its’ action principle. Apparently pretreatment with 
erlotinib, or concomitant administration with compound B, might block key molecular pathways and 
regulators for cancer growth and progression such as EGFR pathway or abrogation of RB leading to 
cell cycle arrest (Bonomi, 2003). These processes compromises the cells’ integrity becoming further 
susceptible to a second drug, in this case compound B, which results in increased cell death and a 
lower cell viability. 
Similarly NSCLC A549 cell line’s response to erlotinib and doxorubicin (right chart-Figure 3.5), has 
shown equivalent results although in a less pronounced fashion. While pretreatment with doxorubicin 
for 24 h with posterior administration of erlotinib for another 24 h (1º Dox_Erlo) showed no 
significant alterations, its counterpart, pretreatment with erlotinib for 24 h with posterior 
administration of doxorubicin for 24 h (1º Erlo_Dox) or concomitant administration of both 
compounds for 48 h (Erlo&Dox) have respectively reduced cell viabilities to 30.3 and 27.2 %. Indeed 
these combinations are approximately 1.5 and 1.7 times more active than Dox_SA (45.2 % cell 
viability). However by contrast, the previous combination study employing compound B and erlotinib 
have shown to be 2.9 and 2.6 more active for the same conditions. In view of such results, out of the 
three analysed combination studies, erlotinib plus compound B in combiantion significantly 
demonstrated the most promising results even surpassing the conventional chemotherapeutic drug, 
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doxorubicin under the same conditions. Future studies employing it should be performed in order to 
determine more precisely fundamental parameters such as pharmacodynamics and the possible 
mechanisms of action by identification of main drug-target interactions. 
Despite the observed results judgment should be kept in mind when trying to evaluate the possible 
interactions between compound B, doxorubicin and erlotinib in their respective combination 
strategies. In fact dose-effect relationships between compounds, such as synergistic, additive or 
antagonistic, can only be intuitively extracted from the above results, as no generalized method for 
analyzing dose-effect relationships was used for such cellular systems and strategies (Pinto et al., 
2010). The median effect analysis developed by Chou and Talalayi has been the most renowned and 
currently used method for quantitative evaluation of compound combinations (Chou and Talalayi, 
1984). The method offers a mathematical model based on enzyme kinetic systems and Michaelis–
Menten and Hill equations that allows to correlate the drug dose and the corresponding effect (Chou 
and Talalayi, 1984) and should in future studies be employed to better understand dose-effect 
relationships and how it effects the pharmacokinetic properties of the respective compounds. In other 
words parameters such as synergistic, additive or antagonistic dose-effect relationships should be 
determined alongside with clinical relevant factors like absorption, distribution, metabolism, and 
excretion of the respective compounds and how the concomitantly administration itself affects these 
same factors. 
 3.3. Evaluation of the Apoptotic Potential 
In view of the initial antiproliferative results obtained for chlorogold compounds B and D in NSCLC 
cell lines (A549; H1975) (section 3.1), Hoechst 33258 labeling plus anexinV-FITC and propidium 
iodide double labeling technics were used to explore the underlying mechanisms related to cell 
viability loss. 
 3.3.1. Hoechst 33258 Labeling: Nuclear Morphology Alterations 
Hoechst 33258 fluorescence sensitivity to DNA conformation and chromatin aberrations enable its use 
to detect multiple forms of nuclear damage, being a good indicator of cellular death processes such as 
apoptosis (Hoechst Stains, MP21486, Invitrogen, 2005). Hoechst 33258 ability to bind to AT-rich 
dsDNA strands was used for nuclear staining of NSCLC cell lines, A549 and H1975, when exposed to 
chlorogold compounds (Figure 3.6 and 3.7 respectively), in order to evaluate two main parameters: the 
effects of continuous exposure to chlorogold compounds B and D for 48 h on overall nuclear 
morphology (I) and the underlying mechanism of cell death responsible for cell viability loss when 
exposure to the same compounds (II). 
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Figure 3.6 – NSCLC A549 cell line nuclear staining with Hoechst 33258 in response to 44.4 μM of compound B (B) and 
30.0 μM of compound D (D) bringing to evidence nuclear morphological alterations indicative of apoptosis. Qualitative 
results were compared with the respective solvent of the compounds: 0.1 % (v/v) DMSO (A;C). White arrows point out 
evidences of initial apoptosis hallmarks such as chromatin condensation or aberrant nuclear morphology. White circles 
indicate nuclear fragmentation. 
NSCLC A549 cell line nuclear staining, in response to 44.4 μM of compound B, illustrates several 
nuclei exhibiting clear hallmarks of programmed cell death by apoptosis. Nuclei present themselves 
shrunken with an overall aberrant nuclear morphology and condensed chromatin (Figure 3.6; B; 
arrowheads). Furthermore nuclear fragmentation is also evident as well as the formation of apoptotic 
bodies (Figure 3.6; B; circles). Regarding NSCLC A549 cell line nuclear staining, in response to 30.0 
μM of compound D similar results were observed although to a lesser extent. Paradoxically when 
exposed to compound D, a lower cellular density was observed when in comparison with compound 
B, which in part could be explained considering a hypothetical fast acting mechanism of action for 
compound D consequently justifying for the low number of nuclei. This effect is also visible for 
compound B but less pronounced. These results become considerably more noticeable when in 
contrast with control samples, exposed only to the compounds’ solvent, DMSO. Nuclei in control  
samples present a uniform distribution of fluorescence indicating uncondensed chromatin and normal 
metabolic activity (Silva et al., 2012). One noteworthy fact is the observation of active dividing cells 
in control samples which are not apparent when under compound exposure. The induction of nuclear 
fragmentation and/or the activation of cell cycle arrest processes by possible mechanisms of action of 
the compounds, could offer an explanation for such observations. 
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Similarly the effects of H1975 exposure to compound B and D, on nuclear morphology resemble the 
same as those evidenced for A549. Exposure to 3.36 μM of compound B and 5.43 μM of compound D 
leads to the observation of clear nuclear morphological alterations such as chromatin condensation 
(Figure 3.7; B-D; arrowheads) and nuclear fragmentation (Figure 3.7; B-D; circles). Additionally the 
difference in cell density between control samples and samples exposed to compounds, further 
emphasize the compounds’ capacity to induce cell death, most likely by apoptosis given the presence 
of the exhibited apoptotic hallmarks for the remaining nuclei. 
All in all the results observed in Figures 3.6 and 3.7 correlate with the above cell viability results 
presented in Figure 3.1 and 3.2. There is a clear and marked decrease in cell viability in the presence 
of compound B and D, for both cell lines, which is likely to be intimately correlated with an increased 
cell death by apoptosis (although necrosis cannot be overruled by this assay). 
Figure 3.7 – NSCLC H1975 cell line nuclear staining with Hoechst 33258 in response to 3.36 μM of compound B (B) and 
5.43 μM of compound D (D) bringing to evidence nuclear morphological alterations indicative of apoptosis. Qualitative 
results were compared with the respective solvent of the compounds: 0.1 % (v/v) DMSO (A;C). White arrows point out 
evidences of initial apoptosis hallmarks such as chromatin condensation or aberrant nuclear morphology. White circles 
indicate nuclear fragmentation. 
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 3.3.2. Annexin-FITC and Propidium Iodide Double Labeling: Necrotic vs 
Apoptotic Cells 
 
To consolidate the results obtained for Hoechst staining and in order to get further insights into the 
cytotoxic action of chlorogold compounds in tumour cells, PI and Annexin V-FITC double staining 
was performed to better differentiate between apoptotic and necrotic cell death. Apoptosis is 
distinguished from necrosis by a set of specific molecular and biochemically complex energy 
dependent alterations, involving cytoplasm and chromatin condensation, nuclear aberrations and loss 
of membrane asymmetry. In response to external or internal stimuli, early apoptotic cells rapidly lose 
the asymmetric distribution of the phospholipids in both leaflets typical of viable cells, however 
without losing membrane integrity (Schutte et al., 1998; Brumatti et al., 2008). This early hallmark of 
apoptosis is epitomized by the translocation of the phosphatidylserine from the inner membrane leaflet 
to the outer membrane leaflet which is prone to bind to Annexin V, the Ca
2+ 
dependent phospholipid-
binding protein (FITC Annexin V / Dead Cell Apoptosis Kit with FITC annexin V and PI , for Flow 
Cytometry, MP 13242, Invitrogen, 2010). Plasma and nuclear membrane integrity on the other hand 
decreases in late apoptotic and necrotic cells allowing the nuclear dye PI to pass through membranes 
and intercalate with nucleic acids (Rieger et al., 2011). Flow cytometry employing double staining 
with annexin-FITC and PI can hence discriminate between early and late apoptotic cells from necrotic 
cells. While early apoptotic cells present an FITC
+
/PI
-
 ratio and late apoptotic cells an FITC
+
/PI
+
, 
necrotic cells present an FITC
-
/PI
+
 ratio in view of their membrane integrity characteristics. At risk of 
stating the obvious, viable cells present no staining from both dyes (FITC
-
/PI
-
) (Brumatti et al., 2008; 
Sabbadini et al., 2012). 
Flow cytometry results of NSCLC A549 cell line when exposed to compound B and/or doxorubicin 
are illustrated in Table 3.2 and in Figure 3.8. Regarding the control sample, cells exposed only to 0.1 
% (v/v) DMSO, showed an intact cytoplasmic membrane, evidenced by a demarking large percentage 
of viable cells (89.9 %), with only a small percentage of apoptotic cells. In respect to the exposure of 
NSCLC A549 cell line to 44.4 μM of compound B, the percentage of non-stained (FITC-/PI-) viable 
cells decreases significantly from 89.9 % to 55.4 % in what represents a total 1.6 fold change. Parallel 
to the decrease in cell viability, a considerable subpopulation of cells, exhibiting hallmarks of late 
apoptosis (FITC
+
/PI
+
) experience a substantial increase in an order of magnitude of approximately 5.4 
fold higher (7.5 to 40.8 %) when compared with 0.1 % (v/v) DMSO. These results become even more 
pronounced with a 1.5 fold increase in compound B concentration. A 66.6 μM compound B exposure 
induces high numbers of late apoptotic cells (FITC
+
/PI
+
), reaching a total number of 74.7 %. Indeed 
when compared to 0.1 % (v/v) DMSO this value represents an astonishing 10 fold increase in the 
number of late apoptotic cells. For the remaining subpopulations (FITC
+
/PI
-
, FITC
-
/PI
+
) no significant 
alterations were observed (Table 3.2), however for all three conditions analysed (0.1 % (v/v) DMSO; 
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0.1% DMSO
Compound B 
(44.4 μM)
Compound B 
(66.6 μM)
Doxorubicin 
(9.20 μM)
Doxorubicin 
(13.8 μM)
Compound B & 
Doxorubicin
Viable Cells 89.95 (± 2.07) 55.36 (± 14.53) 21.19 (± 14.54) 5.26 (± 2.42) 10.59 (± 7.81) 4.23 (± a)
Early Apoptotic Cells 1.87 (± 1.68) 1.48 (± 0.27) 2.67 (± 0.76) 25.17 (± 15.36) 26.96 (± 16.15) 17.63 (± a)
Late Apoptotic Cells 7.51 (± 1.75) 40.84 (± 13.89) 74.77 (± 15.11) 46.35 (± 9.58) 39.86 (± 7.23) 75.68 (± a)
Necrotic Cells 0.67 (± 0.46) 2.31 (± 0.79) 1.36 (± 0.53) 23.22 (± 15.07) 22.59 (± 15.23) 2.46 (± a)
compound B 44.4 and 66.6 μM) the bulk of apoptotic cells were found to increase in a dose-dependent 
way and to mainly have late apoptosis hallmarks, hence exhibiting a double staining pattern 
(FITC
+
/PI
+
). The relevance of such noteworthy evidence, comes from the fact that a higher proportion 
of cells in latter stages of apoptosis is indicative of the compound’s ability to induce apoptosis in a 
more readily fashion, and consequently of a potentially faster mechanism of action.  
Both the hypotheses of a potentially faster mechanism of action as well as the induction of cell death 
by apoptosis (and not necrosis) are strongly corroborated with the initial results presented for Hoechst 
33258. In face of the results obtained for cell viability assays, Hoechst 33258 staining and flow 
cytometry data, a substantial increase in the sub-population of late apoptotic cells seems to be linked 
to the underlying mechanism of cell death of chlorogold compounds. Based on these evidences, 
chlorogold compounds are able to induce cell death by apoptosis in a dose-dependent fashion and 
through potentially faster mechanism of action. 
Table 3.2 – Total percentage of viable, early apoptotic, late apoptotic and necrotic cells, in NSCLC A549 cell line, when 
exposed to different concentrations of compound B and doxorubicin or when exposed to both compounds in combination at 
their respective IC50 values. Cells treated with 0.1% (v/v) DMSO were used as control. Data was analysed by flow cytometry 
after Annexin-V/FITC and PI double staining. Data values are referent to those reported in Figure 3.8, and are represented as 
means ± SEM of at least three independent experiments. 
a – Not available 
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Figure 3.8 – Proportion of viable, apoptotic and necrotic cells in NSCLC A549 cell line, when exposed to different concentrations of compound B and doxorubicin or when exposed to both in 
combination at their respective IC50 values. Cells treated with 0.1% (v/v) DMSO were used as control. Data was analysed by flow cytometry after Annexin-V/ FITC and PI double staining. The 
data is represented as means ± SEM of at least three independent experiments. 
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Regarding the exposure effects of NSCLC A549 cell line to doxorubicin the evidenced results show a 
very distinct distribution of viable, apoptotic and necrotic cells when compared with compound B’s 
results. Administration of 9.20 μM of doxorubicin (IC50 value) promotes an abrupt decrease in cell 
viability when compared with 0.1 % (v/v) DMSO, presenting only an approximately 5 % of cells with 
intact cytoplasmic membrane (FITC
-
/PI
-
). Plus the bulk of apoptotic and necrotic cells present an 
increase of 7.6 and 34.6 fold respectively. In comparison with administration of 44.4 μM of compound 
B (IC50 value), doxorubicin exhibited 50 % less viable cells, which were followed by an increase of 
23.7, 5.5, and 20.9 % more early apoptotic (FITC
+
/PI
-
), late apoptotic (FITC
+
/PI
+
) and necrotic cells 
(FITC
-
/PI
+
) respectively. Also of interest, the administration of doxorubicin’s IC50 value (He et al., 
2011), paradoxically induces cell death values substantially above 50 % which even considering the 
concept of relative IC50 values is an odd fact. Such result can be explained as part of the limitations of 
MTS cell viability assay. In particularly the rationality behind the MTS assay stems from the 
spectrophotometric readings of the formazan resultant from the reduction of the set of tetrazolium 
reagents, by metabolically active cells (Wang et al., 2010). This fact alone translated into other words 
means that IC50 values obtained through MTS cell viability assay are often overestimated, 
consequently explaining this paradigm. Furthermore a 1.5 fold increase in doxorubicin’s 
concentration, opposed to what was observed for compound B, did not dramatize the initial effects 
obtain for the respective IC50 value. In fact unlike what was expected the percentage of viable cells 
actually increased from 5.2 to 10.6 % and late apoptotic cells actually decreased (Table 3.2). Despite 
these results the distinct distribution of viable, apoptotic and necrotic cells when compared with 
compound B, seems to point out to the distinct mechanisms of action between the two compounds. 
In view of these results and taking into consideration the use of agents with different mechanisms of 
action as one of the fundamental principles for combination chemotherapy (Mayer and Janoff, 2007), 
the rational step of analysing the combination therapy of doxorubicin and compound B by flow 
cytometry was performed in order to assess its effect in NSCLC A549 cell line as complementary 
study of combination therapies already mentioned above. The concomitant administration of 
doxorubicin and compound B at their respective IC50 values evidenced clear patterns of the 
mechanisms of action of both compounds (Figure 3.8). Indeed as shown in Table 3.2, only 4.2 % of 
the cells are considered as viable, in a total decrease of 85.7 % in cell viability compared with 0.1 % 
(v/v) DMSO. Similar values were obtained for doxorubicin at its IC50 value (approximately 84.7 %). 
Plus the numbers of early apoptotic cells also seem to follow a pattern similar to that obtained for 
doxorubicin either at 9.20 μM or 13.8 μM. Evidencing a total value of 17.6 % of early apoptotic cells, 
only 9.3 % separate it from doxorubicin’s value at 13.8 μM, while when compared with compound B 
at 66.6 μM this difference increases to approximately 15 %. Conversely a more thorough analysis on 
late apoptotic and necrotic cells, evidences patterns almost identical to those presented for compound 
B at 66.6 μM. By putting in contrast both tested conditions, compound B at 66.6 μM and the 
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simultaneous administration of doxorubicin and compound B at the respective IC50 values, early 
apoptotic cells’ values are only set apart by 0.9 % thus emphasizing the possible influence of 
chlorogold compound B in inducing a fast acting apoptotic process when in combination. Considering 
necrotic cell value variance between the mentioned conditions these are also not substantial, being 
apart only by 1.1 %.  
Again these results ―push‖ towards an hypothesis were the administration of both compounds 
simultaneously is accompanied by the observation of a hybrid therapeutic effect (here evidenced by 
flow cytometry), characterized by the merging of the different mechanisms of action of both 
compounds. 
 3.4. Cell Cycle Evaluation: Cell Cycle Arrest 
The intricacy of the biochemical events and molecular mechanisms that regulate cell cycle and 
apoptosis are intimately linked (Al-Rubeai and Singh, 1998). The delicate balance between the 
regulatory processes that govern cell cycle can either prevent or induce an apoptotic response. Tumour 
suppressor genes TP53 and RB, C-MYC oncogene and CDKs (Pucci et al., 2000), comprise the main 
orchestrators that supervise and regulate such responses, and that ultimately establish the link between 
cell cycle and apoptosis responses. For instances p53 may mediate cell cycle arrest in response to 
DNA damage and eventually in face of un-repairable damage entry of the cell into apoptosis (Vousden 
and Prives, 2009). 
Cell cycle evaluation was performed in order to better understand the molecular mechanisms 
underlying the therapeutic activity of chlorogold compounds, while simultaneously assessing its 
applicability and effects on cell cycle progression, alone and in combination with doxorubicin. These 
cell cycle studies also allowed to understand whether loss of viability through the induction of 
apoptosis could be preceded by alterations in cell cycle progression and in cell cycle checkpoints.  
Table 3.3 – Total percentage of NSCLC A549 cells at different stages of the cell cycle, when exposed to compound B and 
doxorubicin at their respective IC50 values either in single agent treatment or in combination therapy. Data was analysed by 
flow cytometry after propidium iodide (PI) staining of DNA. Cells treated with 0.1% (v/v) DMSO were used as control. Data 
values are referent to those reported in Figure 3.9, and are represented as means ± SEM of at least two independent 
experiments. 
 
 
0.1 % DMSO B B & Dox 0.1 % DMSO B B & Dox 0.1 % DMSO B B & Dox
27.71  (± 2.56) 38.96  (± 2.33)
9.49  (± 1.46) 10.42  (± 2.78) 52.33  (± 1.70) 15.71  (± 2.16) 11.34  (± 2.69) 28.13  (± 1.26) 31.45  (± 8.91) 10.75  (± 1.41)13.32  (± 2.77)
38.96  (± 2.59) 57.52  (± 3.23) 29.34  (± 2.87) 38.19  (± 7.25)
51.55  (± 2.39) 32.06  (± 0.45) 18.34  (± 3.30) 46.1  (± 5.56)
G1/G0 
S 
G2/M
3h Exposure 6h Exposure 9h Exposure
32.2  (± 3.35 )
53.47  (± 2.92)
44.14  (± 6.54) 62.78  (± 1.77) 40.84  (± 6.39) 50.29  (± 0.92)
44.52  (± 9.24) 9.1  (± 0.84)
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Figure 3.9 – Effect of compound B in single agent treatment and of compound B and doxorubicin in combination therapy on NSCLC A549 cell cycle. Cells were treated with 0.1% (v/v) DMSO 
as control of the experiment or with 44.4 μM compound B and compound B & Dox at their respective IC50 values during different time points (3, 6, 9 h). DNA was stained with propidium 
iodide, and DNA content was analysed by flow cytometry. The data are represented as means ± SEM of at least two independent experiments.  
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Exposure of NSCLC A549 cell line to 0.1 % (v/v) DMSO for a period of 3 h evidences the majority of 
the cells in S-phase (53.5 %) and a small subpopulation under G1/G0 phase (32.2 %) (Table 3.3 and 
Figure 3.9). This pattern evidenced for the control sample is probably a reminiscent effect of the 
synchronization at early S-phase with the double thymidine block procedure. The 3 h exposure period 
for compound B exhibits a similar effect to that evidenced for 0.1 % (v/v) DMSO with 51.5 % cells in 
S-phase and approximately 38.9 % in G1/G0 phase. Combination therapy employing compound B and 
doxorubicin on the other hand exhibited the most contrasting results, with a significant proportion of 
cells under G1/G0 phase reaching 57.5 % of the total number, while S-phase exhibited approximately 
32.0 %. Considering doxorubicin’s ability to bind to TOPO II and consequently disrupting DNA/RNA 
synthesis and topoisomerase-II-mediated DNA repair system the last results presented fit to the 
described mechanism of action. DNA damage induced by doxorubicin could induce p53 activation 
causing G1 arrest by inducing p21 expression and consequent inhibition of CDKs/Cyclin D complexes 
(Pucci et al., 2000). Samples that were submitted under 6 h exposure period showed substantial 
differences compared to the control sample 0.1 % (v/v) DMSO (6 h) (Table 3.3; Figure 3.9). 
Conversely compound B exposure and compound B plus doxorubicin in combination, evidence 
similar results, and differences throughout cell cycle phases between each condition do not exceed a 
1.38 fold discrepancy. When compared with 0.1 % (v/v) DMSO (6 h), the same conditions show 
differences in S- and in G2/M phase. While compound B demonstrates a 2.5 fold increase and a 3.3 
fold decrease for S- and in G2/M phase respectively, combination therapy manifested a 2.4 fold 
increase and a 4.6 fold decrease, being these differences initial indications of cell cycle arrest, 
especially when compared with 3 h exposure samples. The fact that no significant alterations were 
observed between 3 h and 6 h exposure samples, namely for the samples exposed either to compound 
B or the combination therapy reinforces the concept of abrogation of cell cycle progression (Figure 
3.9). At 9 h exposure period, the proportion of subpopulations throughout the different cell cycle 
stages also exhibit differences in comparison with 0.1 % (v/v) DMSO (9 h), emphasizing the idea of 
the continuity of the cell cycle progression for the control samples, while the remaining test samples 
present a non-linear cell cycle progression with contrasting ―anomalies‖ (Figure 3.9). A more detailed 
analysis demonstrates that the most significant differences are evidenced for the percentage values 
between S-phases. In fact compound B and combination therapy display a 2.9 and a 4.3 fold increase 
respectively when compared with 0.1 % (v/v) DMSO (9 h) (Figure 3.9). Putting in contrast compound 
B at 6 h and at 9 h exposure a 1.7 fold decrease is evidenced between the S-phase and a 2.0 fold 
increase for G2/M phase indicating that despite an apparent S-phase delay, the cell cycle continues to 
advance (Figure 3.9). The same is not the case for compound B and doxorubicin in combination where 
no significant differences were observed between the 3 and 6 h exposure samples. Indeed the 
differences presented do not exceed the 1.1 fold discrepancy throughout all the cell cycle phases. This 
effect shown for the combination therapy suggests that the delay effect demonstrated for compound B 
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in single agent treatment is actually not only is maintained in combination therapy with doxorubicin as 
well as it is potentiated, the latter being more evident for 9 h exposure period (Figure 3.9).  
Comparing the percentage values of the different cell cycle phases for all control samples (3, 6 and 9 
h) it is apparent that the cell populations that were in S- and G2/M phase progressed towards G1/G0, 
and the ones that were in G1/G0 progressed to S- and G2/M phase (Figure 3.9). The transition 
between cell cycle phases is not so evident and linear when cell populations’ were exposed to either 
compound B or the combination therapy (Figure 3.9). Overall the results here presented for the 
different time-points seem to point out for the progression of the cell cycle for the control samples, 
while cells submitted to either compound B or doxorubicin demonstrated clear signs of cell cycle 
―drag‖ and cell cycle arrest, this effect being, especially evident for S-phase.  
In view of these results the apparent stalled cell cycle progression during S-phase could indicate the 
possible molecular targets of compound B and of the combination therapy. Namely the formation of 
CDK2/cyclin A complex by complexation of both regulators, is a master orchestrator of secondary 
specific and intricate mechanisms responsible for DNA polymerases, histones and proliferating cell 
nuclear antigen, inextricably involved in DNA synthesis (Lapenna and Giordano, 2009). Stalled cell 
cycle progression in S-phase may result from the possible targeting of any of these regulators involved 
in DNA replication that trigger the intra-S-phase checkpoint responsible for the transition S — G2/M. 
In fact several chemotherapeutic drugs are known to induce the intra-S-phase checkpoint pathway, 
consequently blocking S-phase progression (Karnani and Dutta, 2011). Some reports have shown that 
the intra-S-phase checkpoint is responsible for regulating replication fork progression. In this sense 
any DNA lesion or hindrances of the molecular machinery responsible for the replication process 
could induce checkpoint activation and consequently cell cycle delay/arrest (Grallert and Boye, 2008). 
This checkpoint signaling could eventually result in the activation of apoptotic pathways if the 
respective cellular damage cannot be repaired (Pietenpol and Stewart, 2002). 
In order to understand whether cell cycle arrest occurs and to verify the possibility of an intra-S-phase 
checkpoint pathway activation, quantitative RealTime-PCR (qRT-PCR) studies on the genes involved 
in the replication machinery and in intra-S-phase checkpoint would be fundamental. Comparative 
proteomic studies would also be paramount to understand the intricacy of the regulators involved. 
Reported proteins involved in intra-S-phase checkpoint that would be critical to understand these 
results include the CDK2/cyclin A complex and other cellular factors directly phosphorylated by 
ataxia telangiectasia mutated (ATM), such as BRCA1, E2F-1 and others (Bartek and Lukas, 2001). 
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 3.5. Compound-DNA Interactions 
  3.5.1. UV-Vis Spectroscopy Analysis 
For the large percentage of the chemotherapeutic drugs currently employed,  DNA is often the 
primary intracellular target, and the consequent interactions generally cause broad spectrum damage 
leading to a myriad of cellular responses that frequently culminate in either cell cycle arrest or in cell 
death. UV/Vis absorption spectrophotometry was performed in order to draw conclusions on the 
possible interactions of chlorogold compounds with the DNA molecule, further contributing for the 
understanding of the molecular mechanisms involved in cell cycle arrest and apoptotic responses. 
Recurrent interactions between metal complexes and double helix DNA include intercalation, groove 
binding or external electrostatic binding (Palchaudhuri and Hergenrother, 2007; Shahabadi and 
Mohammadi, 2012; Satyanarayana et al., 1993). DNA interactions through intercalation or in an 
electrostatic dependent manner are typically characterized by alterations of the spectral features of 
DNA regarding its double helix structure. Namely these types of interactions are generally 
characterized by hypochromism and red shift (bathochromism). Hypochromism corresponds to a 
decrease in the samples’ absorption spectra associated with intercalation, while hyperchromism, an 
increase in the samples’ absorption spectra, is typically ascribed to electrostatic binding or to uncoiling 
of the DNA double helix (Shahabadi et al., 2011; Cox et al., 2009). 
UV/Vis absorption spectrophotometry studies aimed at the analysis of specific parameters such as 
hyperchromic/hypochromic and bathochromic effects in order to determine the specific modes of 
interaction between chlorogold compounds and CT-DNA, while simultaneously evaluating the 
respective intrinsic affinity binding constants (Kb) of each compound, obtained through the shift in 
absorbance values for the maximum wavelength value (Yousuf et al., 2014). According to the data 
shown the absorption spectra of the compounds B and D in the presence or absence of CT-DNA 
displayed in Appendix C, did not reveal a peak of absorbance values for a specific wavelength making 
it impossible to determine and characterize the type of interaction with the DNA as well as the 
intrinsic binding affinity constants. The integrity of the chlorogold compounds’ structure in solution (5 
mM Tris-HCl (Merck), 50 mM NaCl (Panreac), pH 7 buffer) is possibly a key interfering factor in the 
absorption spectra of each compound. In view of the inability to obtain significant results through UV-
Vis spectroscopy these studies were not further investigated. In the future, studies regarding the 
stability and hydrosolubility of compounds B and D should be emplaced in order to further understand 
the reason for such results. 
 3.5.2. DNA cleavage assay 
Initial compound-DNA interaction studies based on UV-Vis spectroscopy analysis retrieved no 
significant results possibly as consequence of weak compound stability in aqueous solution. In an 
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attempt to obtain further insights on the possibility of chlorogold compounds (B and D) interacting 
with DNA, supplementary studies were employed. In this regard the ability of chlorogold compounds 
to bind and cleave the DNA molecule was assessed, through the exposure of plasmid DNA (pDNA) 
pUC18 to increasing concentrations of the tested compounds for 24 h at 37 ºC and consequently 
submitting the corresponding products to agarose gel 0.7% (w/v) electrophoresis (Figure 3.10 and 
Figure 3.11). The rationale behind this DNA cleavage assay is based on the fact that the intact double-
stranded plasmid DNA is normally in a compact circular closed formation known as the supercoiled 
isoform. Under physical aggression supercoiled DNA strands can be cleaved, being the end result 
distinct whether one, or two strands are damaged. Assuming that the supercoiled DNA sustains only 
one break in one of the strands the DNA acquires a more relaxed conformation known as open circular 
DNA or Nicked DNA isoform. The DNA will remain circular however the break allows for rotation 
along its own central axis, the phosphodiester backbone, hence releasing the supercoils. Following a 
cleavage event on the complementary strand near the first cleavage site the conformation is reduced to 
a linear isoform (Palchaudhuri and Hergenrother, 2007; Silva et al., 2011). Accordingly to the 
conformation acquired by the pDNA molecule, dependent on the interaction with the compounds, 
different migration rates are observed when these are subjected to agarose gel electrophoresis. A small 
compact supercoiled DNA isoform experiences considerably less friction against the agarose matrix 
than compared to an open circular DNA isoform which is translated to a relatively fast migration 
observed for the supercoiled DNA. Linear isoform one the other hand runs through a gel end first and 
consequently sustains less friction than the open circular DNA isoform but more than the supercoiled, 
positioning itself between these two isoforms in the agarose gel matrix (Neves, 2001).                    
 
 
 
 
 
 
Figure 3.10 – Exposure effect of 200 ng of pUC18 plasmid DNA to either 0.62 % (v/v) DMSO or to increasing 
concentrations of compound B (0, 10, 30, 60 80, 100, 150, 200 μM). Resulting products of a 24 h exposure period at 37 ºC 
were submitted to electrophoresis in agarose gel 0.7 % (w/v) (upper panel). λ/HindIII – molecular weight marker; C – control 
with plasmidic DNA pUC18; DMSO – control with DMSO at 0.62 % (v/v) without compound; L – Linearized pUC18 with 
EcoRI. I – Supercoiled isoform; II – Nicked isoform (not shown); III – Linear isoform. pUC18 plasmidic DNA isoform 
distribution, illustrated in the bar chart (lower panel) was obtained through software analysis tool GelAnalyzer. 
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Figure 3.11 – Exposure effect of 200 ng of pUC18 plasmid DNA to either 2.23 % (v/v) DMSO or to increasing 
concentrations of compound D (0, 60, 80, 100, 150, 200, 250, 300 μM). Resulting products of a 24 h exposure period at 37 ºC 
were submitted to electrophoresis in agarose gel 0.7 % (w/v) (upper panel). λ/HindIII – molecular weight marker; C – control 
with plasmidic DNA pUC18; DMSO – control with DMSO at 0.62 % (v/v) without compound; L – Linearized pUC18 with 
EcoRI. I – Supercoiled isoform; II – Nicked isoform (not shown); III – Linear isoform. pUC18 plasmidic DNA isoform 
distribution, illustrated in the bar chart (lower panel) was obtained through software analysis tool GelAnalyzer. 
A closer analysis over compound B (Figure 3.10) and compound D’s (Figure 3.11) effect on the 
conformation of pUC18 plasmid DNA reveals that these compounds do not present the ability to either 
bind/cleave the DNA molecule or to change its conformation in any form. The absent interaction of 
chlorogold compounds B and D, with the pDNA molecule is evident throughout increasing 
concentrations on both cases. In fact a 20 fold concentration increase for compound B (from 10 to 200 
μM) and a 5 fold concentration increase for compound D (from 60 to 300 μM) does not increase the 
extent of pDNA degradation and hence no substantial differences in the proportion of pDNA isoform 
conformations were observed, with exception for slight variations of the linear isoform, a pattern 
similar for both compounds. This effect however is unlikely to be the direct result of the chlorogold 
compounds’ ability to induce double strand breaks on pDNA since this pattern is highly inconstant 
over the increasing concentrations and not significantly different from the control sample values (0.62 
and 2.23 % (v/v) DMSO for compound B and D respectively). The possibility of an intact and 
undamaged form of supercoiled pDNA to give rise to circular or linear isoforms by random cleavage, 
through either enzymatic or chemical aggression (freeze/thaw cycles), of one or both strands (Li et al., 
2011; Iuliano et al., 2002) offers the most reasonably explanation for such results and observed 
patterns. In short these results demonstrate no interactions between chlorogold compounds and the 
pDNA molecule for the tested concentrations and hence the molecular mechanism underlying the 
antiproliferative activity so far revealed by the same compounds are implausible to be related to any, 
adduct,  intercalating or electrostatic type interaction, and can be considered to occur by DNA-
independent processes. In fact recent mechanistic studies employing a wide variety of cytotoxic gold 
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compounds, have similarly demonstrated their ability to induce broad apoptosis, however manifesting 
considerably lower affinity for DNA when compared with blockbuster platinum(II) compounds, thus 
suggesting a DNA-independent mechanism of action (Bindoli et al., 2009). In similarity to other 
cytotoxic gold compounds the results here obtain for compound B and D push towards the hypothesis 
of the existence of preferential protein targets for such compounds. Key protein targets such as TrxR 
involved in the redox potential homeostasis, or the proteasome system involved in protein and 
organelle turnover, have been the most consensual targets listed in the literature (Bindoli et al., 2009; 
Lima and Rodriguez, 2011). Enzymatic assays employing such targets should be considered 
paramount for the understanding of the molecular mechanisms that govern the cytotoxicity of these 
chlorogold compounds. 
 3.6. Proteome Evaluation: Comparative Proteomics 
Proteome evaluation through the use of 2-DE gel electrophoresis was established as a mean to 
construct a broader scale comparative proteome profile between NSCLC cell lines (A549 and H1975) 
when subjected to chlorogold compound exposure in order to better understand the molecular 
mechanisms underlying the biological activity of these coordination compounds while identifying the 
major affected biochemical pathways. Due to time limitation factors and methodology-related 
hindrances such as the difficulty in obtaining sufficient amounts of biological material to perform the 
analysis, comparative proteome profiling was performed only between A549 and HCT-116 cell line 
under the exposure of 0.1% (v/v) DMSO for a period of 48 h. The rationale behind the use of HCT-
116 cell line in this study stems from the fact that the majority of the identified proteins in our research 
group were performed in this cell line, and as such it was used as a support platform for facilitating 
protein identification in NSCLC A549 cell line.  
The two dimensional gel electrophoresis of the whole protein extract from the two cell lines were 
performed twice and the representative protein patterns of HCT-116 and A549 cell lines are illustrated 
in Figure 3.12. Protein quantitative analysis was performed by the normalization of the volume 
percentage of each spot, relatively to the total spots per sample. The Melanie 7.0 program allowed to 
detect approximately a total of 482 and 417 protein spots in HCT-116 and A549 respectively. 
Furthermore image analysis identified a total of 405 spots shared between the two cell lines out of 
which 25.17 % are found to be less abundant in A549 and 30.46 % more abundant relatively to HCT-
116 cell line. The total number of proteins that were possible to be identified by previous characterized 
gels and that exhibited significant differences in abundance are depicted in Table 3.4. 
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Figure 3.12 – Comparative proteome profiling of HCT-116 (left) and A549 (right) cell lines when subjected to 0.1 % (v/v) 
DMSO for an exposure period of 48 h. 2-DE gels were obtained from at least 200 μg of whole protein extract and resulting 
spots were stained with Comassie Blue. Spots whose abundance variance levels were considered significantly altered were 
marked and number tagged. 
 
Table 3.4 – Proteome evaluation: Total number of proteins identified in 2-D gel electrophoresis, with the indication of the 
spot ID referent to figure 3.7, UniProt ID, protein identification, isoelectric point, molecular weight, function and abundance 
variance levels between HCT-116 and A549 cell lines. Proteins whose abundance variance levels were considered 
significantly altered were highlighted. Values under 0.7 (red) and above 1.5 fold (green) were taken into account. 
Spot ID UniProt ID Protein Identification pI 
MW 
(KDa) 
Fold Change 
Protein 
Function 
1 CALR_HUMAN Calreticulin 4.29 48.11 0.58 
Chaperone/Stress 
response 
2 CALR_HUMAN Calreticulin 4.29 48.11 0.14 
Chaperone/Stress 
response 
3 TCPQ_HUMAN 
T-complex protein 1 
subunit theta 
5.42 59.58 2.08 
Cytoskeleton 
mobility 
4 HS90B_HUMAN 
Heat shock protein HSP 
90-beta 
4.97 83.21 - 
Chaperone/Stress 
response 
5 P4HB_HUMAN 
Protein disulfide-
isomerase 
7.17 36.69 0.52 
Protein 
binding/Folding 
6 ENOA_HUMAN Alpha-enolase 7.01 47.13 1.94 Metabolism 
7 RANG_HUMAN 
Ran-specific GTPase-
activating protein 
5.19 23.29 2.04 
Signal 
transduction 
8 1433Z_HUMAN 14-3-3 protein zeta/delta 4.73 27.73 2.25 
Signal 
transduction 
9 DHE3_HUMAN 
Glutamate 
dehydrogenase 1, 
mitochondrial 
7.66 61.36 0.66 
Component 
turnover/Detox 
10 PHB_HUMAN Prohibitin 5.57 29.79 1.82 
Protein 
binding/Folding 
11 HSP7C_HUMAN 
Heat shock cognate 71 
kDa protein 
5.37 70.85 0.32 
Chaperone/Stress 
response 
12 HS90B_HUMAN 
Heat shock protein HSP 
90-beta 
4.97 83.21 0.54 
Chaperone/Stress 
response 
13 GRP75_HUMAN 
Stress-70 protein, 
mitochondrial 
5.87 73.63 0.63 
Chaperone/Stress 
response 
14 CH60_HUMAN 
60 kDa heat shock 
protein, mitochondrial 
5.08 45.44 0.39 
Protein 
binding/Folding 
15 HSP71_HUMAN 
Heat shock 70 kDa 
protein 1A/1B 
5.48 70.01 0.65 
Chaperone/Stress 
response 
  MW MW 
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16 HSP71_HUMAN 
Heat shock 70 kDa 
protein 1A/1B 
5.48 70.01 0.59 
Chaperone/Stress 
response 
17 ATP5B_HUMAN 
ATP synthase subunit 
beta, mitochondrial 
5.57 40.20 - Metabolism 
18 PRDX2_HUMAN Peroxiredoxin-2 6.27 49.77 9.69 
Signal 
transduction 
19 RSSA_HUMAN 
40S ribosomal protein 
SA 
4.79 32.83 0.57 Other 
20 GDIR1_HUMAN 
Heat shock protein beta-
1 
5.84 45.95 1.86 
Chaperone/Stress 
response 
21 SODC_HUMAN 
Superoxide dismutase 
[Cu-Zn] 
5.70 15.93 2.16 
Component 
turnover/Detox 
22 TPIS_HUMAN 
Triosephosphate 
isomerase 
5.65 30.77 1.59 Metabolism 
23 EZRI_HUMAN Ezrin 5.94 69.37 - 
Cytoskeleton 
mobility 
24 HSP71_HUMAN 
Heat shock 70 kDa 
protein 1A/1B 
5.48 70.01 0.28 
Chaperone/Stress 
response 
25 ENPL_HUMAN Endoplasmin 4.76 92.41 0.54 
Chaperone/Stress 
response 
26 EZRI_HUMAN Ezrin 5.94 69.37 0.58 
Cytoskeleton 
mobility 
27 XRCC6_HUMAN 
X-ray repair cross-
complementing protein 
6 
6.23 69.79 1.73 Other 
28 RBBP7_HUMAN 
Histone-binding protein 
RBBP7 
4.89 47.82 1.52 
Signal 
transduction 
29 PA2G4_HUMAN 
Proliferation-associated 
protein 2G4 
6.13 43.76 9.81 
Signal 
transduction 
30 IF4A2_ HUMAN 
Eukaryotic initiation 
factor 4A-II 
6.74 95.30 - Other 
31 PA2G4_HUMAN 
Proliferation-associated 
protein 2G4 
6.13 43.76 5.70 
Signal 
transduction 
32 TCPB_HUMAN 
T-complex protein 1 
subunit beta 
6.01 57.45 1.80 
Protein 
binding/Folding 
33 ENOA_HUMAN Alpha-enolase 7.01 47.14 2.28 Metabolism 
34 EZRI_HUMAN Ezrin 5.94 69.37 0.52 
Cytoskeleton 
mobility 
35 SGTA_HUMAN 
Small glutamine-rich 
tetratricopeptide repeat-
containing protein alpha 
4.81 44.08 4.04 
Chaperone/Stress 
response 
36 
ANXA2_ 
HUMAN 
Annexin A2 6.79 98.92 1.78 
Chaperone/Stress 
response 
37 P5CR1_HUMAN 
Pyrroline-5-carboxylate 
reductase 1, 
mitochondrial 
7.18 33.34 1.54 
Chaperone/Stress 
response 
38 ECH1_HUMAN 
Delta (3,5) -Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
8.16 35.80 - Metabolism 
39 PRDX6_HUMAN Peroxiredoxin-6 6.00 25.02 - 
Component 
turnover/Detox 
40 1433Z_HUMAN 
14-3-3 Protein 
zeta/delta 
4.73 27.73 1.87 
Signal 
transduction 
Spot ID UniProt ID Protein Identification pI 
MW 
(KDa) 
Fold Change Protein Function 
1 CALR_HUMAN Calreticulin 4.29 48.11 0.58 
Chaperone/Stress 
response 
2 CALR_HUMAN Calreticulin 4.29 48.11 0.14 
Chaperone/Stress 
response 
3 TCPQ_HUMAN 
T-complex protein 1 
subunit theta 
5.42 59.58 2.08 
Cytoskeleton 
mobility 
4 HS90B_HUMAN 
Heat shock protein HSP 
90-beta 
4.97 83.21 - 
Chaperone/Stress 
response 
5 P4HB_HUMAN 
Protein disulfide-
isomerase 
7.17 36.69 0.52 
Protein 
binding/Folding 
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6 ENOA_HUMAN Alpha-enolase 7.01 47.13 1.94 Metabolism 
7 RANG_HUMAN 
Ran-specific GTPase-
activating protein 
5.19 23.29 2.04 
Signal 
transduction 
8 1433Z_HUMAN 14-3-3 protein zeta/delta 4.73 27.73 2.25 
Signal 
transduction 
9 DHE3_HUMAN 
Glutamate 
dehydrogenase 1, 
mitochondrial 
7.66 61.36 0.66 
Component 
turnover/Detox 
10 PHB_HUMAN Prohibitin 5.57 29.79 1.82 
Protein 
binding/Folding 
11 HSP7C_HUMAN 
Heat shock cognate 71 
kDa protein 
5.37 70.85 0.32 
Chaperone/Stress 
response 
12 HS90B_HUMAN 
Heat shock protein HSP 
90-beta 
4.97 83.21 0.54 
Chaperone/Stress 
response 
13 GRP75_HUMAN 
Stress-70 protein, 
mitochondrial 
5.87 73.63 0.63 
Chaperone/Stress 
response 
14 CH60_HUMAN 
60 kDa heat shock 
protein, mitochondrial 
5.08 45.44 0.39 
Protein 
binding/Folding 
15 HSP71_HUMAN 
Heat shock 70 kDa 
protein 1A/1B 
5.48 70.01 0.65 
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response 
16 HSP71_HUMAN 
Heat shock 70 kDa 
protein 1A/1B 
5.48 70.01 0.59 
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response 
17 ATP5B_HUMAN 
ATP synthase subunit 
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5.57 40.20 - Metabolism 
18 PRDX2_HUMAN Peroxiredoxin-2 6.27 49.77 9.69 
Signal 
transduction 
19 RSSA_HUMAN 
40S ribosomal protein 
SA 
4.79 32.83 0.57 Other 
20 GDIR1_HUMAN 
Heat shock protein beta-
1 
5.84 45.95 1.86 
Chaperone/Stress 
response 
21 SODC_HUMAN 
Superoxide dismutase 
[Cu-Zn] 
5.70 15.93 2.16 
Component 
turnover/Detox 
22 TPIS_HUMAN 
Triosephosphate 
isomerase 
5.65 30.77 1.59 Metabolism 
23 EZRI_HUMAN Ezrin 5.94 69.37 - 
Cytoskeleton 
mobility 
24 HSP71_HUMAN 
Heat shock 70 kDa 
protein 1A/1B 
5.48 70.01 0.28 
Chaperone/Stress 
response 
25 ENPL_HUMAN Endoplasmin 4.76 92.41 0.54 
Chaperone/Stress 
response 
26 EZRI_HUMAN Ezrin 5.94 69.37 0.58 
Cytoskeleton 
mobility 
27 XRCC6_HUMAN 
X-ray repair cross-
complementing protein 
6 
6.23 69.79 1.73 Other 
28 RBBP7_HUMAN 
Histone-binding protein 
RBBP7 
4.89 47.82 1.52 
Signal 
transduction 
29 PA2G4_HUMAN 
Proliferation-associated 
protein 2G4 
6.13 43.76 9.81 
Signal 
transduction 
30 IF4A2_ HUMAN 
Eukaryotic initiation 
factor 4A-II 
6.74 95.30 - Other 
31 PA2G4_HUMAN 
Proliferation-associated 
protein 2G4 
6.13 43.76 5.70 
Signal 
transduction 
32 TCPB_HUMAN 
T-complex protein 1 
subunit beta 
6.01 57.45 1.80 
Protein 
binding/Folding 
33 ENOA_HUMAN Alpha-enolase 7.01 47.14 2.28 Metabolism 
34 EZRI_HUMAN Ezrin 5.94 69.37 0.52 
Cytoskeleton 
mobility 
35 SGTA_HUMAN 
Small glutamine-rich 
tetratricopeptide repeat-
containing protein alpha 
4.81 44.08 4.04 
Chaperone/Stress 
response 
36 
ANXA2_ 
HUMAN 
Annexin A2 6.79 98.92 1.78 
Chaperone/Stress 
response 
37 P5CR1_HUMAN 
Pyrroline-5-carboxylate 
reductase 1, 
7.18 33.34 1.54 
Chaperone/Stress 
response 
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mitochondrial 
38 ECH1_HUMAN 
Delta (3,5) -Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
8.16 35.80 - Metabolism 
39 PRDX6_HUMAN Peroxiredoxin-6 6.00 25.02 - 
Component 
turnover/Detox 
40 1433Z_HUMAN 
14-3-3 Protein 
zeta/delta 
4.73 27.73 1.87 
Signal 
transduction 
Moreover through bioinformatics analysis and database mining, the identified proteins were classified 
based on their function into various categories, namely chaperone/stress response, metabolism 
cytoskeleton mobility, protein turnover/detoxification, signal transduction and other as shown in 
Figure 3.13. The classification of the respective proteins into specific categories was mainly done by 
recurring to databases such STRING 9.1. The majority of the proteins with substantial abundance 
differences were considered involved in chaperone/stress response mechanisms (35 %) followed by 
protein binding/folding (15 %), signal transduction (15 %) and metabolism (12 %) (Figure 3.13). 
Figure 3.13 – Categorization of the proteome profiling of HCT-116 and A549 into functional categories such as, 
chaperone/stress response, metabolism cytoskeleton mobility, protein turnover/detoxification, signal transduction and other. 
Protein functional properties were based on STRING 9.1 database. The data is referent to table 3.4.  
Analysis of Table 3.4 reveals a total of fifteen proteins with abundance variance levels 1.5 fold higher 
and nineteen proteins with abundance variance levels 0.7 fold lower in A549. Given the extensive 
number of proteins with substantial differences in abundance levels only a few will be addressed here 
and special attention will be given to overexpressed proteins. For instance prohibitin (spot nº10), has 
been found to be 1.82 fold higher in A549 compared with HCT-116 cell line. This protein has been 
correlated with an active role in regulation of cell proliferation but perhaps more importantly to play 
an important part as a regulator of mitochondrial respiration activity and aging. More specifically in a 
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recent study it was evidenced that TNFα and interferon gamma (IFNγ) induced autophagy, was 
inversely correlated with prohibitin protein expression levels. Moreover abrogation of prohibitin 
expression levels through gene silencing methods, in epithelial cells lead to ROS mediated-
mitochondrial autophagy (Kathiria et al., 2012). Translation of this striking correlation between 
prohibitin and abrogation of mitochondrial autophagy, indicates that the higher fold expression level 
evidenced for A549 cell line renders it less susceptible to mitochondrial damage and cytotoxicity. 
These data is in concordance with early assessed IC50 values for both cell lines when exposed to 
chlorogold compounds B and D, where HCT-116 is substantially more impaired than A549 cell line. 
Targeting such protein could in theory promote an increase in mitochondrial autophagy and hence 
reduce the intrinsic resistant nature of NSCLC A549 cell line. As such further investigation on 
prohibitin protein as a potential biomarker and therapeutic target for NSCLC would prove to be 
fundamental and paramount for opening new avenues in cancer therapeutics.  
With an active role in the redox regulation of the cell, peroxiredoxin 2 (protein spot nº 18) was 
strikingly found to be 9.69 times more abundant in A549 when in comparison with HCT-116. Apart 
from redox regulation they have been known to be involved in the process of elimination of peroxides 
generated during metabolism and perhaps more importantly in signaling transduction pathways such 
as of growth factors and TNFα cascades, by regulating the intracellular concentrations of H2O2 (Kim et 
al., 2007). Other literature reports revealed that peroxiredoxin 2 is present both in cytoplasm and 
nucleus of cancer cells where it takes part in a protective role against chemotherapeutic agents (Ishii et 
al., 2012). Peroxiredoxin 2 in the nucleus demonstrated to induce or to facilitate the activation of the 
JNK/c-Jun pathway involved in repair of damaged DNA (Lee et al., 2011). Moreover peroxiredoxin 2 
ability to enhance the aggressive survival phenotype of cancer cells was corroborated by the induction 
of increased cell death and sensitivity to chemotherapeutic agents after recurring to gene silencing by 
siRNA (Ishii et al., 2012; Lee et al., 2011). This information is in line with the findings here 
evidenced and with previous hypothesis also validated by our group, indicating that NSCLC A549 cell 
line is considerably less susceptible to chemotherapeutic treatments. 
Superoxide dismutase [Cu-Zn] (protein spot nº 21) a conserved antioxidant protein responsible for the 
elimination of superoxide radical, resultant from the metabolism plays a protective role against ROS 
(Silva et al., 2013). Indeed the abundance levels in A549 were found to be 2.16 times higher when 
compared to HCT-116. Studies have related the overexpression of superoxide dismutase 1 activity in 
lung cancer cells with an increased growth proliferation rate however without a relationship with cell 
cycle disturbances. Furthermore it was found to related to lower frequencies of programed cell death 
by apoptosis suggesting that the promotion of increased growth proliferation rates are linked to an 
increased survival (Somwar et al., 2011). It is assumed that in view of this data that A549 cell line is 
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considerably less prone to damage induction by ROS, and consequently less susceptible to forms of 
programed cell death such as apoptosis. 
Protein spot number 29 associated with the proliferation-associated protein 2G4 reportedly plays a role 
in ErbB3-regulated signal transduction pathway of growth regulatory signals. Reaching an abundance 
variance of 9.81 fold higher compared to HCT-116, its effect may be intimately connected in growth 
regulation and the promotion of oncogenic functions (Kim et al., 2012). Recent studies on a long 
isoform of the ErbB3 binding protein, when overexpressed evidenced the capacity to induce 
differentiation processes involved in malignant transformation (Kim et al., 2012). This fact might help 
explain the aggressive nature of p53 positive NSCLC cell lines such as A549. 
Furthermore α-enolase (protein spot nº 33) expression levels are also substantially different (2.28 fold 
increase). Considered to be a multifunctional enzyme, playing diverse roles such as growth control, 
hypoxia tolerance and allergic responses, it is although more renowned for its part as metabolic 
enzyme involved in glycolysis and in the consequent synthesis of pyruvate (Chang et al., 2006; 
Capello et al., 2011). The overexpression profile of this protein in A549 it is not itself a surprising 
evidence as the re-modulation of energy metabolism is typically considered a transition hallmark from 
normal cells to tumour cells, where glycolysis develops into the main metabolic pathway to sustain 
and support the synthesis of nucleotides, fatty acids, amino acids and other macromolecules for the 
accelerated mitosis (Warburg effect) (Marie and Shinjo, 2011). However recent studies have 
correlated the expression status of α-enolase with different clinical outcomes regarding tumour 
malignancy, survival and tumour recurrence in NSCLC. Moreover the substantial difference observed 
in A549 in comparison with HCT-116 offers new possibilities for prognostic strategies and new 
targeted therapy for NSCLC (Chang et al., 2006) 
Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) (Protein spot number 
35) was similarly found to be overexpressed by 4.04 fold in comparison with HCT-116. Interestingly 
these results seem to be in accordance with recent literature data, reporting high expression values in 
NSCLC (Xue et al., 2013). Furthermore overexpression of this protein has shown to be significantly 
correlated with critical processes involved in tumour growth and differentiation. Suppression of SGTA 
expression dramatically influenced the proliferation rate of A549 cell line and cell cycle progression. 
In fact cell cycle analysis transiently suppressed by siRNA revealed an accumulation of cells in the 
G0/G1 phase and helped to correlate the expression of cell cycle proteins such as cyclin A and cyclin 
D1 with the expression of SGTA (Xue et al., 2013). 
All in all comparative proteomic studies were initially ought to be performed for A549 cell line when 
subjected to chlorogold compounds’ exposure in order to compare proteome profiles of cell samples 
with and without chemotherapeutic stress, thus helping to trace the molecular mechanisms involved in 
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the cytotoxic activity of such coordination compounds. As mentioned above, methodology-related 
hindrances did not allow the successful realization of the initially established goals. However A549 
and HCT-116 cancer cell line comparison by two-dimensional gel electrophoresis allowed to point out 
significant differences between these distinct cancer cell lines, opening new possibilities in targeted 
therapies and in the identification of new potential biomarkers for prediction of prognosis in NSCLC. 
Being the leading cause of cancer related death worldwide (Gridelli et al., 2007), the importance of 
these and other similar studies could have not been more stressed. The findings here presented and 
discussed for prohibitin, peroxiredoxin 2, superoxide dismutase [Cu-Zn], proliferation-associated 
protein 2G4 and for SGTA may have potentially new applications in the field of oncology.  
 3.7. Morphological Characterization of Human Colorectal and Lung 
Adenocarcinoma Cell Lines with Multidrug Resistance  
Accordingly with the secondary objective established in this work it was expected to set up the 
foundations for a study platform for multidrug resistance, in order to decipher the underlying 
mechanism that orchestrate it, and to understand the implications of newly established combination 
chemotherapies as means to overcome drug resistance. 
By long term exposure of HCT-116 and A549 cell lines to doxorubicin, it was established a series of 
subcultures that were considered to be at the initial stages of acquired multidrug resistance. HCT-116 
cell line exposure to a step wise increase in doxorubicin concentration that ranged from 0.001 μg/mL 
to 0.5 μg/mL, and from 0.0058 μg/mL to 0.029 μg/mL for A549 cell line, induced the acquisition of 
morphological features that accordingly to literature reports are consistent with early signs of 
multidrug resistance. In fact compared with parent cells, resistant cell lines A549/R were in general 
smaller at low confluence mixed with considerably large cells in different sizes (results not shown) 
which is in accordance with similar studies (Wang et al., 2006). HCT-116/R cells on the other hand 
were substantially smaller and presented a higher tendency to grow in organized cell clusters (results 
not shown).  
As a result of the unfinished process of multidrug resistance induction, (only a total of 15 out of 30 
subcultures were carried out under the presence of doxorubicin) parameters such as the 
chemoresistance indexes were not evaluated. Future studies in view include the assessment of such 
chemoresistance indexes as well as the performance of genomic and post-genomic analysis regarding 
the amplification of the human MDRI expression, and/or the relative increase in the amount of 
membrane P-glycoproteins or their activity.  
72 
 
4. Conclusions and Future Perspectives 
The interdisciplinary and constantly evolving nature of chemotherapeutics consistently offers new and 
ingenious possibilities for targeting cancer, however pre-clinical, clinical research and eventually 
clinical translation often poses as a great challenge for the validation and integration of such 
―possibilities‖. The conceptualized hierarchical system of in vitro studies as an integrating part of the 
pre-clinical and clinical research is paramount for the biological evaluation of new anticancer agents 
and strategies. In this work biological evaluation of newly synthesized chlorogold complexes through 
a selected set of in vitro studies followed the same logic, in order to understand and describe whether 
or not the compounds were effective against cancer cells while simultaneously unraveling related 
mechanisms of action. 
The antiproliferative evaluation of chlorogold complexes bearing phosphine or N,O-donor ligands, 
was carried out across a panel of tumoural and non-tumoural cell lines available. The most active 
compounds Chloro(trimethylphosphine)gold(I) (compound B) and Chloro(triphenylphosphine)gold(I) 
(compound D) displayed the ability to inhibit cell proliferation in a dose-dependent manner across the 
panel of tumoural cell lines. A549 cell line exposure to compound B and compound D displayed an 
IC50 value of 44.4 and 30.0 μM, plus 3.3 and 5.4 μM in H1975 cell line respectively suggesting that 
chlorogold compounds confer antiproliferative properties in vitro for both tumoural cell lines. 
Nonetheless it is worth noting that for these cell lines both compounds revealed to less active than 
clinically employed renowned agents such as doxorubicin or cisplatin. Cytotoxicological analysis of 
compound B and D, further performed in normal human dermal fibroblast revealed IC50 values of 7.74 
and 19.10 μM respectively translating into a 5.7 and a 1.6 fold higher toxicological effect for 
healthy cell lines when compared with tumoural cell line A549. Such analysis would suggest that 
these chlorogold compounds present some significant setbacks when considering systemic 
toxicity; hence a hypothetical translation into clinical setting would have to take into 
consideration strategies to circumvent such hindrances. Targeted therapies, such as nanocarriers 
as drug delivery platforms show great potential for overcoming these toxicity related issues, and 
the viability of their employment should be assessed in future studies. 
Combination chemotherapy studies were performed upon an effort to target cancer’s typical hallmarks 
with particular focus on resistance to chemotherapeutics in order to improve patient’s outcomes. It was 
tested different combination therapies in three distinct sequences defined in section 2.5.1. Particularly 
cell viability assay in NSCLC A549 cell line, in response to the combination of compound B and 
doxorubicin, erlotinib and compound B, or erlotinib and doxorubicin were assessed as potential tools 
for combination chemotherapy. In summary the investigated combination therapies revealed variable 
degrees of antiproliferative potential. More specifically pretreatment with doxorubicin for 24 h with 
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posterior administration of compound B for another 24 h revealed to be the most effective 
combination while pretreatment with erlotinib for 24 h with posterior administration of compound B 
elicited the weakest antiproliferative effect. To gain further insights on the quantitative evaluation of 
the compounds combinations future studies based on the median effect analysis developed by Chou 
and Talalayi should be employed. 
After selection of compound B and D as the most active compounds from the initial screen, further in 
vitro analysis based on a number of properties associated with the mechanisms of action were 
determined. The apoptotic potential, evaluated by Hoechst 33258 for A549 and H1975 cell lines 
revealed the ability of the compounds to induce chromatin condensation as well as nuclear 
fragmentation on both cell lines, being indicative of apoptotic cell death. A549 cell line double 
staining with PI and Annexin V-FITC after exposure to 44.4 and 66.6 μM of compound B evidenced 
that chlorogold compounds are able to induce cell death by apoptosis in a dose-dependent fashion and 
potentially through a fast acting mechanism. Administration of 9.20 and 13.8 μM of doxorubicin in 
turn revealed an abrupt decrease in cell viability as well with a parallel increase in the bulk of 
apoptotic and necrotic cells. Combination chemotherapy employing both compounds was 
accompanied by the observation of a hybrid therapeutic effect possibly characterized by the merging 
of the different mechanisms of action of both compounds. 
A549 cell line exposure to compound B and the combination therapy with compound B plus 
doxorubicin throughout different time points evidenced demonstrated clear signs of cell cycle ―drag‖ 
and cell cycle arrest, this effect being, especially evident for S-phase. Moreover the assessment of the 
compounds’ ability to interfere with cell cycle main regulators and in intra-S-phase, such as Cyclin E/ 
CDK2 and Cyclin A/ CDK2 through RT-PCR could eventually prove to be paramount to obtain 
further insights into the mechanism of action of the complexes, more specifically regarding the 
process by which the cell cycle is impaired. Plus other cellular factors directly phosphorylated by 
ataxia telangiectasia mutated (ATM), such as BRCA1, E2F-1 could provide more insights on the 
subject.  
The attempts to obtain tangible and reproducible absorption spectroscopic data were proven 
unsuccessful and information regarding the type of interaction with the DNA as well as the intrinsic 
binding affinity constants was ―unachievable‖. The integrity of the chlorogold compounds’ structure 
in solution is possibly a key interfering factor in the absorption spectra of each compound and hence 
additional avenues must be explored as means to obtain these data. DNA cleavage assays on the other 
hand indicated that compound interaction with the DNA molecule was proven to be either weak or 
inexistent, revealed by the compounds’ inability to compromise plasmid DNA conformation. 
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Proteomic studies envisaged a further investigation into the mode of action of the chlorogold 
compounds with a particular interest to identify target proteins involved stress response, multidrug 
resistance, apoptosis, cellular signaling as well as cell cycle regulation and overall cellular 
homeostasis. Time limitation factors and methodology-related hindrances such as the difficulty in 
obtaining sufficient amounts of biological material to perform the analysis were at core of the 
impotence to obtain enough data regarding the molecular mechanisms and the target through which 
chlorogold compounds develop their cytotoxic activity. Despite not conclusive regarding chlorogold 
compounds’ mechanism of action, the few data gathered allowed for the identification of potential 
important biomarkers for prediction of prognosis in non-small-cell lung carcinoma. Proteins such as 
prohibitin, peroxiredoxin 2, superoxide dismutase [Cu-Zn], proliferation-associated protein 2G4 and 
for SGTA may open new avenues and lay the ground work for potentially new applications in the field 
of oncology. In the future to fully understand the molecular targets of the chlorogold compounds it is 
imperative to trace the proteome profiles in A549 and H1975 cell lines. 
Also given the extensive literature on the ability of gold compounds to interact with TrxR it would be 
interesting to assess the compounds’ ability to promote enzyme inhibition plus the ability to induce 
ROS by a glutathione s-transferase assay. 
Overall the unique cellular and biochemical aspects of each tumor, such as their heterogeneity and 
continuously evolving nature continue to hinder the success of currently established therapies and the 
emergence of new strategies. Well-established in vitro studies as those here employed are increasingly 
more important as demands for a better quality of treatment for one the epidemics of the twenty-first 
century become progressively stricter. Parallel to the development of novel more effective drugs and 
to meet up with demands new drug delivery systems based on nanoscale devices showing new and 
improved pharmacokinetic and pharmacodynamics properties like enhanced bioavailability, high drug 
loading or systemic stability have surged in the past decade as promising solutions to the required 
therapeutic efficacy. Merging chlorogold compounds with the toolbox of nanotechnology and 
nanoscale drug delivery devices offers a virtually endless number of possibilities to target cancer and 
should be conceptualized for future work. 
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Appendix A 
Chemical structure of the assayed chlorogold compounds and related information. 
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Appendix B 
Compound B and compound D cytotoxic evaluation across a library of tumoural and non-tumoural 
cell lines 
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Appendix C 
Erlotinib single drug treatment cytotoxic evaluation in A549 NSCLC cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e 
 
Appendix D 
Spectroscopic analysis of chlorogold compounds B and D bound and unbound to CT-DNA: UV-
visible titrations 
 
 
 
 
 
 
 
 
 
 
 
